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The causes of beta cell dysfunction and loss in feline diabetes mellitus (FDM) are 
incompletely understood.  Potential causes of beta cell failure include amyloid 
accumulation, oxidative stress, inflammatory cytokine signaling, and endoplasmic 
reticulum (ER) stress.  GLP-1 and GLP-1 mimetics have been proposed to have a beta 
cell sparing effect by mitigating cellular stress and pro-apoptotic signaling resulting from 
these causes, thereby inhibiting cell death.  The purpose of the work described herein was 
three fold: to identify cellular mechanisms associated with beta cell dysfunction in FDM, 
to develop techniques for the use of freshly isolated feline islets for the study of islet cell 
dysfunction in cats, and to study the mechanisms and utility of GLP-1 mimetics as a 
therapy of FDM.  Firstly, we tested the hypothesis that the pancreatic islets of cats with 
FDM have increased inflammation, oxidative stress, and pancreatic amyloid as compared 
to apparently healthy control cats.  The results of this study suggest that oxidative 
modification and inflammatory cytokine signaling are present in the normal feline islet 
and increase with obesity and hyperglycemia.  Secondly, we developed techniques for the 
isolation and culture of fresh feline pancreatic islets for in vitro study.  Viability of islets 
was maintained for at least 5 days.  An inconsistent response to glucose stimulated 
insulin production and release was seen in isolated islets, suggesting a lack of normal 
physiologic responsiveness of the islets.  Thirdly, ER stress was induced in freshly 
isolated islets and the protective effect of the incretin mimetic exenatide was evaluated.  
Exenatide treatment resulted in a reduction of apoptotic signaling secondary to induced 
ER stress.  Lastly, the clinical utility of incretin mimetics as an adjunct therapy for FDM 
was tested in a clinical trial evaluating insulin alone versus insulin with adjunct 
exenatide.  Exenatide was not associated with improved glycemic control in cats, but 
results suggest a potential benefit of weight loss in obese diabetic cats.  The study was 
limited by the small sample size resulting in a statistically underpowered study.  
Investigations in a larger population of diabetic cats are needed to assess the potential 
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INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Introduction  
The incidence of feline diabetes mellitus (FDM) is as much as 15 times higher now than 
what was reported 40 years ago, making it one of the most common endocrinopathies seen in 
domestic cats.  The disease has significant potentially negative effects on patient quality of life, 
the human-animal bond shared with the patient’s owner, and overall patient longevity.  The 
causes of this increase in disease incidence are incompletely understood.   
Diabetes mellitus is the clinical manifestation of a failure of glucose homeostasis 
resulting in uncontrolled hyperglycemia.  Although the mechanisms underlying this failure are 
varied and involve the interplay between many different neurohormonal pathways, it is ultimately 
the failure of insulin activity on sensitive tissues that results in the major clinical manifestations. 
The cellular mechanisms leading to a lack of insulin effectiveness involves decrease of 
peripheral insulin sensitivity in tissues such as adipose or skeletal muscle and the inability of 
pancreatic beta cells to produce sufficient hormones to elicit a peripheral effect.  Insulin is the 
primary secretory product of pancreatic beta cells found within the islets of Langerhans.  Beta 
cells sense changes in glucose in the interstitial space and insulin release is promoted in the face 
of rising glucose and inhibited in times of decreasing glucose.   
2 
 
1.2 Epidemiology of feline diabetes mellitus 
Several studies have investigated the incidence of FDM.  It was estimated that the 
incidence of feline diabetes was 0.08% in 1970, but by recent accounts is now estimated to be as 
high as 1.2%.1,2    
Feline diabetes mellitus and type 2 diabetes mellitus in people share many striking 
similarities.  Both diseases are rooted in an inherent resistance of peripheral tissues to the effects 
of insulin and a subsequent period of hyperinsulinemia.  Both are associated with so-called “life 
style” factors such as poor diet, inactivity, and obesity.  In both diseases, it is pancreatic beta cell 
exhaustion that ultimately leads to uncontrolled hyperglycemia and clinical signs.  In many cases, 
early detection and reversal of these lifestyle factors may result in remission of disease and return 
to euglycemic control.   
There are many possible explanations for the increase in diagnosed cases of feline 
diabetes.  Insulin resistance leading to an increased burden on the pancreas to maintain 
euglycemia appears to be central to the development of both type 2 diabetes in people and feline 
diabetes.  The effects of obesity on the prevalence of diabetes cannot be overstated and an 
epidemic of obesity in both people and cats is well documented.3,4 Obesity in cats is strongly 
associated with feline diabetes, with obese cats being 3.9 times more likely than lean cats to 
develop diabetes.5 It is well documented that obesity in people is associated with decreased 
insulin sensitivity.  The same correlation has been made in multiple experiments in cats.  In one 
study cat study, weight gain of as little as 1kg was associated with a 30% decrease in insulin 
sensitivity.6 In another study, an increase in body weight of 44% resulted in a 52% decrease in 
insulin sensitivity.7    
It is also evident that genetic predispositions are associated with development of feline 
diabetes.  The increased incidence of diabetes in Burmese cats (2.9-3.7 times more likely 
compared to other breeds) suggests a genetic predisposition in this breed.8,9 Furthermore, a 
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polymorphism in the melanocortin 4 receptor gene has been positively correlated with frequency 
of diabetes in both obese and lean cats.10 
 
1.3 The anatomy of the Islet of Langerhans 
Named for the German medical student who identified islands of cells within the 
exocrine pancreas that did not appear to be responsible for the digestion of food, Islets of 
Langerhans comprise approximately 3% of the cat pancreas by weight.11 Islets, regardless of 
species or location within the pancreas, are comprised of 5 primary endocrine cell lines, each with 
it’s own secretory hormone products:  alpha (glucagon), beta (insulin, islet amyloid polypeptide), 
delta (somatostatin), epsilon (ghrelin), and PP (pancreatic polypeptide).  Islets are not 
homogenous in their size and cellular makeup.  They can range from as few as a dozen cells to 
several thousand cells.12 In the cat, the cells comprising the largest percentage of the islet are the 
beta cells, which comprise roughly 60% of the volume of the islet and are found typically along 
the periphery with some clusters within the interior of the islet.12 (Figure 1.1)  This is in contrast 
to mouse islets, which are composed of nearly 80% beta cells that are arranged within the core of 
the islet.  Human islets are roughly 50% beta cells and arranged more randomly than is reported 






Figure 1.1. The feline islet is comprised of 5 primary cell types.  The beta cells tend to 
form a ring, or mantle, around a core of alpha, delta, epsilon, and PP cells.  Islets have rich 





1.4 Neuroendocrine regulation of euglycemia 
Neuroendocrine control of serum glucose is largely dependent on insulin activity, but 
also relies heavily on the effects of glucagon, islet-associated polypeptide, incretins (e.g. gastric 
inhibitory peptide and glucagon-like peptide-1), and the sympathetic nervous system.   
 
1.4.1 Secretory products of the beta cell: insulin 
Insulin is the primary secretory product of the pancreatic beta cells.  Regulation of 
expression of the insulin gene is complex, and under the control of many different binding 
elements in the insulin promoter region.  Glucose-regulated promotion of insulin gene 
transcription is largely under the influence of pancreatic and duodenal homeobox-1 (PDX-1), 
neurogenic differentiation 1(NeuroD1), V-maf musculoaponeurotic fibrosarcoma oncogene 
homologue A (MafA), and Pax6.13-15 Also, products of the MAPK system and CRE binding 
elements are all potent promoters of insulin expression.13 Inhibitors of insulin expression include 
c-Jun and CCAAT-enhancer binding protein beta (c/EPBβ).14 The specific mechanisms 
associated with promotion or inhibition of insulin production by individual hormones or drugs are 





Figure 1.2. Biosynthetic pathway of insulin in the beta cell. 1: PC1 begins the process of 
separating the alpha and beta chains fro the c-peptide during transport through the ER. 2: 
Proinsulin is chaperoned from the ER to the golgi.  3: During transit through the golgi network, 
PC2 activity further separates the c-peptide from the alpha and beta chains while three disulfide 
bonds are formed.  4: Newly formed secretory vesicles are lower in density.  The continued 
activity of PC2 and carboxypeptidase-E complete the processing of insulin, resulting in mature 
insulin consisting of an alpha and beta chain (joined by two disulfide bonds) as well as the c-
peptide chain.  5: as vesicles mature, they increase in density as insulin crystalizes to form the 




Initial processing is completed by prohormone convertase 1/3 (PC1) within the 
endoplasmic reticulum.  As the protein is chaperoned through the trans-golgi network, 
prohormone convertase 2 (PC2) provides the second enzymatic cleavage of proinsulin.  Once 
packaged inside the secretory vesicle, the actions of carboxypeptidase-E (in concert with PC2) 
provide the final modification, releasing the c-peptide fragment from insulin, which is now a 
5.8kD protein comprised of a 21 amino acid alpha chain and a 30 amino acid beta chain with 
three disulfide bonds.16 Both of these products (insulin and c-peptide) are released in equimolar 
concentrations. (Figure 1.2) 
Secretory vesicles increase in density as their core becomes more acidified and the 
insulin monomers precipitate into a crystalline pentameric structure.  Within the vesicles, insulin 
crystals are stabilized by interactions with zinc (and to a lesser extent islet associated polypeptide) 
at a low pH (pH 5.5).17 Insulin crystals make up the majority of the dense core of the granule, 
with c-peptide and IAPP molecules comprising much of the halo region around the core.18     
Docking of secretory granules and exocytosis is SNARE-dependent and initiated by 
increases in cellular calcium and membrane depolarization. The primary stimulation for insulin 
release is an increase in the ATP:ADP ratio in the cell.  ATP concentration increases in response 
to an influx of glucose into the beta cell (via the bi-directional and constitutively expressed 
GLUT-2 receptor).  Higher concentrations of ATP trigger inactivation of the potassium/ATP 
pump, leading to membrane depolarization and opening of the voltage-gated calcium channel in 
the cell membrane.  The membrane-bound potassium/ATP channel is also inactivated by 
increased cytosolic cyclic AMP which is the result of adenylyl cyclase activation secondary to 






Figure 1.3: Increases in cytosolic calcium trigger docking and exocytosis of beta cell granules.   
Beta cells “sense” glucose in the interstitial space due to the high-affinity, bi-directional nature of 
the GLUT-2 transporter.  Increases in ATP/ADP ratio secondary to mitochondrial respiration 
induce a closure of the potassium ATPase transport which initializes depolarization and opening 
of the voltage-dependent calcium channel.  Both GLP-1 and GIP activate adenylyl cyclase and 
the increase in cytosolic cAMP activates the Epac2 protein.  Muscarinic stimulation from 
parasympathetic neurons (vagus nerve) increases cytosolic calcium via DAG/PKC pathway.  
Ligand binding to GPR40 also results in increased cytosolic calcium, but the precise mechanism 







1.4.2 Secretory products of the beta cell: IAPP 
Islet amyloid polypeptide (IAPP) is the second most abundant secretory product of the 
pancreatic beta cells.  Historically, IAPP has also been referred to as amylin because misfolded 
IAPP forms islet amyloid.  This terminology can be confusing, thus the name IAPP has become 
more widely accepted.  Transcription of IAPP is regulated and promoted similarly to insulin.   
IAPP is translated as a 67amino acid prohormone that is processed by PC1 and PC2 to a mature, 
3.9kD, 37 amino acid peptide with a single disulfide bond between cysteine residues at position 2 
and 7.19 IAPP is trafficked alongside insulin and packaged within secretory vesicles.20 Within 
these vesicles, the mature insulin and IAPP form a stable crystal structure (along with zinc ions) 
within the dense core of the granules.  In the dense core there is between 25 and 50 times more 
insulin than IAPP.18 
IAPP has several beneficial physiologic effects in the body including stimulating satiety, 
suppressing food intake, delayed gastric emptying, and inhibiting meal-associated glucagon 
secretion. 21-23 
 
1.5 The incretin effect 
In 1906, a group of researchers at the University of Liverpool published the first work 
describing the treatment of diabetes mellitus in people using the extract of duodenal mucous 
membranes from pigs.  In their work they described the effects of “secretin”, which was shown to 
increase exocrine pancreatic secretion and had a glucose lowering effect on the body.24,25 It was 
clear that compounds associated with the gut mucosa had a profound effect on the function of the 
pancreas and, prior to the discovery of insulin, it was hoped that these compounds could be useful 
in treating diabetes mellitus.26 In 1932, a Belgian physician named Dr. Jean La Barre and his 
collaborator, Dr. Zunz, documented the hypoglycemic effect of duodenal extracts in normal 
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animals that was abolished in pancreatectomized animals.  They named the substances 
responsible for this phenomena “incretins”, a term still in use today.27 
By the early 1960s, it was possible to measure plasma insulin in people.  In 1964, what is 
now known as the incretin effect was first described by two separate groups.28,29 The incretin 
effect is defined as the magnified release of insulin in response to a dose of glucose given 
enterally as compared to an equivalent dose given intravenously.  The effect can be profound, 
accounting for as much as 60% of the increase in insulin after oral ingestion of glucose in a 
healthy adult human.30,31 The hormone responsible for this response was unknown until 1970, 
when a new hormone named gastric inhibitory peptide was purified from duodenal extracts.32 A 
second major incretin, glucagon-like polypeptide, was not described until 1980.33 The incretin 
effect has been demonstrated in many species, including people, dogs, rodents, and cats.34,35 
 
1.5.1 Incretin Hormones 
The incretin effect described above is due principally to the effects of two hormones.  
Gastric inhibitory peptide (GIP) and glucagon-like polypeptide (GLP-1) are products of 
specialized enteroendocrine cells.  GIP is produced by K-cells and GLP-1 is a product of L-cells.  
GLP-1, like glucagon, is a product of the proglucagon gene.  In the alpha cells of the pancreatic 
islets, expression of prohormone convertase 2 (PC2) leads to production of glucagon and major 
pro-glucagon fragment (MPGF).  MPGF appears to be biologically inactive.  In intestinal L-cells, 
expression of PC1 leads to production of GLP-1, GLP-1, and glicentin. (Figure 1.4)  The largest 
amount of GLP-1 is produced by L-cells in the small intestine and colon. There is some minor 
variability of location of these cells within the gut of different animals.30,36 It has been shown in 
the cat that GLP-1 positive L-cells are found throughout the gut, but are concentrated in the 
ileum.  GIP is produced within K-cells that are equally distributed throughout the feline gut.  
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Unlike what is observed in other species, K-cells and are not concentrated in the adoral portions 






Figure 1.4:  Proglucagon is differentially processed in the intestinal L-cells and the brain 
where PC1 is highly expressed.  This results in the major products GLP-1, GLP-2, and glicentin.  
In the pancreatic alpha cells, PC2 is highly expressed.  Here, the resulting products are glucagon, 







GLP-1 has an extremely short half-life in the body (1-2 minutes in people) due to the 
effects of dipeptidyl peptidase-4 (DPP4).38 DPP4 is ubiquitously expressed in the body and is 
found both free and tissue-bound forms.  DPP4 is a serine protease enzyme that cleaves the two c-
terminal amino acids from active GLP-1 (7-36), thereby generating the inactive metabolite GLP-1 
(9-36).  Of the total GLP-1 produced by the L-cells, only 25% reaches portal circulation and only 
10% reaches the caudal vena cava and systemic circulation.30 
Stimulation of K and L-cells occurs in response to nutrient exposure from luminal 
contents of the gut.  The nutrients responsible for the strongest stimulation of these cells vary 
slightly between species.  In the cat, unlike in people, release of GIP is highest in response to 
lipids and amino acids, but minimal to glucose.  Conversely, GLP-1 release in cats was equally 
stimulated by glucose, amino acids, and lipids.34 The response of GIP to lipids and amino acids 
was much more robust than that seen in people, whereas the response of GLP-1 to lipids and 
amino acids was much weaker than that seen in people.39   
One potential interpretation of these findings is that this pattern of response is consistent 
with the natural history of the cat.  As an obligate carnivore, the cat should be more responsive to 
lipids and amino acids and less responsive to simple carbohydrates.  Studies completed in people 
have shown the incretin effect is blunted in people who are obese or Type 2 diabetic but this has 
not been investigated in cats.40 
 
 1.5.2 Effects of GLP-1:  Insulin production and release 
GLP-1 acts both directly and indirectly on pancreatic beta cells to potentiate acute phase 
insulin release.  The effect of GLP-1 on vagal afferents elicits a vagal-vagal reflex and will 
produce immediate muscarinic stimulation of insulin release from the beta cells.41-43 The GLP-1 
receptor is a g-protein coupled receptor and ligand binding of the GLP-1r on beta cells induces 
14 
 
adenylyl cyclase, which in turn activates two parallel pathways by which GLP-1 potentiates acute 
insulin release.  Increases in cytosolic cAMP inactivate the membrane-bound potassium ATPase 
and assists in depolarization of the cell membrane.43 Additionally, the increasing cytosolic cAMP 
activates the EpacII “exchange protein activated by cyclic AMP-2”.43 EpacII directly inactivates 
the potassium ATPase pump and binds the ryanodine receptor on the endoplasmic reticulum, 
thereby increasing cytosolic calcium.23  (Figure 1.5) 
 
 1.5.3 Effects of GLP-1: Beta cell sparing effects 
Of particular interest in regards to therapeutic implications are the supportive effects 
GLP-1 exerts on the beta cells, generally characterized as anti-apoptotic, pro-proliferative, and 
anti-inflammatory.44-52 GLP-1 has been shown to decrease the severity of the unfolded protein 
response during periods of endoplasmic reticulum stress in the beta cell.53 GLP-1 is a potent 
promoter of the PDX-1 gene in the pancreatic beta cell.49,54 The PDX-1 promoter is central to beta 
cell secretory, replicative, and survival mechanisms.49,55-57 GLP-1 has been shown to confer anti-
apoptotic protection against cytokine-induced and hyperglycemic apoptosis in both insulinoma 






Figure 1.5: GLP-1 signaling in the pancreatic beta cell has three primary results.  It is 
antiapoptotic via the Akt, ERK1/2, and CREB/PDX-1 pathways.  Insulin secretion is enhanced by 
Epac2 closure of the potassium ATPase channels assisting in membrane depolarization.  GLP-1 




Pancreatic beta cells demonstrate remarkable plasticity.  Although typically a long-lived 
cell type in healthy individuals, beta cell neogenesis, duplication, differentiation, and expansion 
are seen when insulin demands exceed the capacity of the current beta cell population.59 GLP-1, 
via cAMP/PKA and MAPK, promotes beta cell replication and expansion through activation of 
cyclin D.60 Partially pancreatectomized mice treated with a GLP-1r agonist maintained greater 
beta cell mass and better glucose tolerance as compared to control mice.61 Pretreatment of mice 
with exendin-4 (a synthetic GLP-1 receptor agonist) prior to administration of streptozotocin 
resulted in significantly lower blood glucose and increased oral glucose tolerance, suggesting a 
beta cell sparing effect of GLP agonists.47 This effect was lost on GLP-1R knockout mice.  In 
streptozotocin treated newborn mice, GLP-1 stimulated beta cell neogenesis and led to a nearly 
normal glucose tolerant phenotype.62 Goto-Kakizaki rats are born with limited beta cell mass and 
rapidly become insulin-dependent diabetics.  Experiments have shown in juvenile Goto-Kakisaki 
rats that two months of treatment with GLP-1 and GLP-1 mimetics was associated with a 
significant reduction in blood glucose and expansion of beta cell mass.63 Not only can new beta 
cells be generated by expansion of existing beta cells, but it is also apparent that pools of 
pluripotent stem cells within islets and ductal epithelium can be induced to differentiate into 
insulin producing beta cells under the influence of GLP-1.64 Direct inhibition of apoptosis by 
GLP-1 and GLP-1 mimetics has been demonstrated in multiple cell lines.46,47,58,65  
GLP-1 has been shown to have many activities in the body outside of its effects on the 
beta cell.  In the brain, GLP-1 triggers satiety signals, promotes neural stimulation of insulin 
release via the vagal nerve and has been suggested to help inhibit the deposition of the amyloid-
beta plaques typical of Alzheimer’s patients.66 In the heart, GLP-1 increases intracellular calcium 
and has positive inotropic and chronotropic effects.31   
The effects of GIP appear to be more limited.  GIP receptors are in the same family of G-
protein coupled receptors as GLP-1R, and are found in the gut, pancreatic beta cells, brain, and 
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bone.  Binding of GIP to its receptor results in an increase in cyclic AMP via activation of 
adenylyl cyclase.  GIP has been shown to inhibit apoptosis by an increased expression of Bcl-2 
and decreased expression of Bax in rodent insulinoma and isolated rodent islets.31,38,67,68 GIP and 
GLP-1 together are responsible for the incretin effect in people.30 However, recent studies in the 
cat suggest that the incretin effect in cats is mediated not by GIP, but by GLP-1 alone.34 Whether 
GIP maintains the other positive effects on insulin promotion or in the role of preventing 
apoptotic stimuli has not been evaluated in the cat. 
 
1.6 Mechanisms of Pancreatic Beta Cell Dysfunction 
Our appreciation for the profound complexity of metabolic function and signaling in the 
pancreatic beta cell has continued to evolve as new receptors and metabolic pathways are 
discovered.  It is clear that feline diabetes is a polygenic disease involving many different 
pathways that all ultimately lead to a state of glucose intolerance in the body.  The most 
commonly investigated mechanisms include the relative oxidative state of the beta cell and the 
body as a whole, nutrient intake and relative nutrient load delivered to tissues, tissue sensitivity to 
hormones, disruption of normal cellular signaling in beta cells, alterations in beta cell autophagy, 
and alterations in peripheral insulin sensitivity due to comorbidities such as systemic 
inflammatory conditions and chronic endocrinopathies.   
The function of the beta cell is to be responsive to changes in nutrient load and metabolic 
demands of the body.  As discussed above, the beta cell is able to sense the nutrient load of the 
surrounding interstitial fluid (glucose and NEFAs) and provide a metabolically appropriate 
response in the form of the production and release of the precise amounts of insulin and IAPP 
required to maintain euglycemia and stimulate satiety while providing adequate nutrients to 
insulin sensitive tissues.   
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The most significant mechanisms for beta cell dysfunction, as they are currently 
understood, can be grouped into 5 general categories: gluco-lipotoxicity, inflammation, oxidative 
stress, amyloid accumulation, and endoplasmic reticulum stress.  These categories are not 
mutually exclusive, and most pathways of dysfunction cross over the arbitrary definitions 
presented here.  For instance, the stress of excessive nutrients (as discussed below) is closely 







Figure 1.6:  The interplay between the different causes of beta cell dysfunction is complex.  
Gluco-lipotoxicity is most likely the result of increased oxidative stressors on the beta cells but is 
also associated with increased inflammatory cytokine signaling.  Interleukin-1β plays a central 
role in mediating islet inflammation and IL-1β produced by beta cells acts as both an autocrine 
and paracrine inflammatory mediator.  Hyperglycemia alone is associated with oligomeric 
amyloid formation.  Oxidative stress is both a cause and consequence of inflammation and 
amyloid production.  The role of amyloid is still hotly debated, but it appears clear that oligomers 
of misfolded amyloid are associated with increased oxidative stress and inflammation. 




The phenomenon of glucotoxicity to the beta cell is well established.69,70 Due to the high 
affinity nature of GLUT-2 transporters the beta cell is unable to reduce glucose influx and 
therefore can be exposed to extremely high amounts of glucose during periods of hyperglycemia.  
The most significant mechanism of glucotoxicity involves increases in oxygen free radicals 
secondary to increased metabolic rate and influx of hexose sugars into the beta cell.71 The role of 
oxidative stress is discussed below. Although acute hyperglycemia is a powerful stimulant for 
insulin biogenesis and release, chronic hyperglycemia is associated with a decrease in insulin 
production and loss of PDX-1 and MafA activity.72 Exposure to excessive glucose has been 
shown to decrease the transcription factor Pax6 in INS-1E cells.  As discussed earlier, Pax6 is an 
important promoter for insulin transcription.73 
Excessive glucose is also associated with increased production of carbohydrate adduct 
products on proteins known as advanced glycation end-products (AGEs).  AGEs have been 
shown to be increased in people with decreased insulin sensitivity and in diabetic people.74 In 
rodent insulinoma cell lines and in freshly isolated rodent islets, exposure to AGEs has been 
associated with the production of ROS, increased rates of apoptosis, and decreased insulin gene 
transcription.75-77 
The toxic effects of hyperglycemia on the beta cell have been established in vivo in the 
cat.  Cats experienced profound loss of islet architecture and beta cell mass during a 10-day 
hyperglycemic clamp as compared to saline controls.78 During the 10 day study period, blood 
glucose concentrations were clamped at 25-30mmol/l, a concentration consistent with that of an 
uncontrolled diabetic.  Studies investigating changes in islets under more moderate blood glucose 
conditions, more closely approximating the developing stages of diabetes, are needed to 
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determine the importance of hyperglycemia alone on development of beta cell loss and islet 
destruction. 
 
 1.6.2 Lipotoxicity and the role of GPR-40 
Dyslipidemia characterized by excessive non-esterified fatty acids (NEFAs), increased 
plasma cholesterol, and abnormalities in lipoprotein content are common sequelae of both 
“metabolic syndrome” and type 2 diabetes in people.79,80 The pancreatic beta cell appears to be 
particularly sensitive to the toxic effects of the NEFA palmitic acid.81,82 Insulin resistance and 
feline diabetes are associated with a dyslipidemia in cats as well.83   
Beta cells express a membrane receptor in the g-protein class commonly known as the 
fatty acid receptor or GPR-40.84 Although this receptor is ubiquitously expressed, there is 
particularly high expression associated with the beta cells in mice and people.85-87 It is unknown if 
this receptor is expressed in feline islets. 
Various free (non-esterified) long-chain fatty acids are ligands for this receptor.88 In 
health, binding of NEFAs to GPR-40 potentiates insulin secretion via PLC- mediated increases in 
cytosolic calcium.87 However, in the face of chronic nutrient excess in the form of 
hyperlipidemia, particularly excess palmitic acid, binding of GPR-40 is associated with pro-
apoptotic stress signaling via activation of JNK and MAPK.89, 90  
Although cats do experience a modest dyslipidemia associated with obesity and insulin 
resistance, this is minor in comparison to the degree of dyslipidemia that occurs in people.79,91 
Additionally, cats do not suffer the chronic cardiovascular complications commonly seen in obese 
or diabetic humans such as atherosclerotic plaques and hypertension.  Chronic obesity in cats is 
associated with a more severe dyslipidemia characterized by a VLDL triglyceride fraction 
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increase of 500% as compared to lean control cats.  NEFAs were also increased in the long-term 
obese cat, but the species of NEFA and degree of saturation were not investigated.83,92 In another 
study involving a 10-day hyperlipidemic clamp in which circulating palmitic acid was increased, 
there was little to no change in beta cell function or morphology.93 This was in stark contrast to 
cats subjected to a 10-day hyperglycemic clamp, during which time profound loss of beta cell 
function and mass were observed.78 Taken together, these results suggest that feline beta cells are 
not as sensitive to lipotoxicity as human beta cells.   
 
 1.6.3 Oxidative Stress 
  1.6.3.1 Reactive Oxygen and Nitrogen Species in Health 
Reactive Oxygen Species (ROS) are generated via several pathways.  The majority of 
superoxide radicals are the result of mitochondrial respiration and production of ATP via the 
electron transport chain.  Under a normal metabolic state, superoxide is promptly detoxified by 
the enzyme superoxide dismutase (SOD), a ubiquitous enzyme that exists both within the 
mitochondria (SOD-2) and free in the cytosol (SOD-1).  SOD enzymes utilize the oxidative state 
of metals such as manganese, zinc, or copper to facilitate the addition of protons to the superoxide 
molecule and the creation of hydrogen peroxide.   
Hydrogen peroxide can be further reduced to oxygen and water by the actions of 
glutathione peroxidase using NADPH as electron donor.  Alternatively, hydrogen peroxide may 
also spontaneously react with various metals via the Fenton reaction and produce free hydroxyl 
radicals.  These highly reactive molecules can react with lipids and generate lipid peroxides, 
proteins to create protein carbonyls, or can react with nucleic acids creating unstable 
modifications to DNA.   
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Reactive nitrogen species are ubiquitous and important biological signaling molecules.94 
The action of specific nitric oxide synthase enzymes metabolize arginine to citrulline and create 
nitric oxide.  Nitric oxide is a commonly employed second messenger in smooth muscle causing 
relation of muscle fibers.   
It is important to realize that exposure to free radicals such as reactive oxygen and 
nitrogen species is not always detrimental to the cell.  Oxygen free radicals, hydrogen peroxide, 
and nitric oxide all contribute to the overall REDOX state of the cell and are known to serve as 
second messengers or signaling molecules.94 Problems develop when there is an imbalance in 
REDOX potential producing an excess of oxygen radicals or a lack of antioxidant protection.   
 
  1.6.3.2 Reactive Oxygen and Nitrogen Species in Disease 
Because many oxidative modifications are relatively stable, it is common to use their 
presence as an indicator of oxidative stress or damage to the cell.  Reactive oxygen species 
interacting with membrane lipids can generate oxidized lipids.  The most commonly quantified 
markers of oxidative modification of lipids are malondialdehyde as measured by the 
thiobarbituric acid reactive substance test (TBARS) or hydroxynonenal (4-HNE).  Oxidative 
modification of proteins can be the result of direct amino acid oxidation, lipid aldehyde adducts, 
or the result of reactive nitrogen species (RNS) interacting with certain amino acid side chains 
resulting in a variety of covalent modifications including 3-nitrotyrosine (3NT).  In the nucleus, 
oxygen free radicals interact with nucleic acids and can produce adducts, single and double strand 
breaks, or relatively benign modification of individual nucleic acids.  8-hydroxyguanosine (8-
OHG) is routinely used as a marker of oxidative damage to nucleic acids. Techniques using 
directed antibodies can be used to identify and quantify oxidative modifications such as 4-HNE, 




  1.6.3.3 ROS and RNS in Beta Cell Dysfunction 
The exact role of oxidative stress and oxidative stress induced damage in beta cell 
function and dysfunction is not clear.  In mice and people it has been shown that beta cells, as 
compared to other metabolically active tissues, have a fairly weak antioxidant capacity.95-98 This 
peculiarity has led to several theories regarding the role of oxidative stress and beta cell 
dysfunction.   
Beta cells are intended to respond rapidly to ambient nutrition in the intercellular space.  
The beta cell is somewhat different than other cells in that the glut-2 transporter expressed by beta 
cell does not allow for regulation of nutrient influx into the cell.  Therefore, the metabolic rate of 
the beta cell is set not by its needs but by the availability of nutrients (namely glucose).  As 
described above, glucose (and other hexose sugars) are rapidly metabolized and shuttled into 
mitochondrial respiration for the generation of ATP (a process required to induce insulin release 
in response to an increased ATP:ADP ratio in the cell).  However, when the electron transport 
chain becomes overwhelmed, or when ATP content of the cell is exceedingly high, the proton 
gradient across the mitochondrial membrane can be “short-circuited” and allowed to leak.  This 
will slow the production of ATP, but also generates an increase in free radical generation.  This 
short circuit is largely due to the expression and activity of uncoupling protein 2 (UCP-2), which 
has been shown to be up-regulated in beta cells in response to nutrient excess.99,100   
Alterations in oxidative signaling or increases in oxidative stressors on the beta cell will 
induce a wide range of response and adaptive mechanisms including down-regulation of beta cell 
secretory products, up-regulation of NF-κB, and activation of JNK.95,101-104 Experiments in freshly 
isolated rat islets exposed to oxidative stress have demonstrated a rapid reduction in insulin gene 
promotion and nuclear export of PDX-1.95,105 Induction of the NF-κB pathway is complex and 
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can be associated with a cytoprotective and pro-proliferative response in the beta cell.  However, 
aberrant signaling resulting from excessive or chronic stimulation of NF-κB is associated with 
increased pro-inflammatory gene products (such as interleukin-1), induction of inducible nitrate 
synthase (iNOS), and ultimately induction of apoptosis.  Activation of c-Jun N-terminal kinases 
by excessive ROS formation is also associated with a decline in beta cell function and induction 
of beta cell apoptosis.103  
There have been no studies to date investigating the precise role of oxidative stress on the 
feline pancreatic beta cell.  Additionally, there have not been any studies describing the 
antioxidant capacity of the feline beta cell to determine if it is relatively deficient in antioxidant 
capacity similar to what has been described in people and rodents.  Although data is lacking 
regarding the local pancreatic antioxidant capacity in the cat, the evidence is mixed regarding 
whether cats experience increased levels of whole body oxidative stress similar to that seen in 
both obese and Type 2 diabetic people.6,83,106-110 
 
 1.6.4 Amyloid 
Pancreatic amyloid protein is composed of aggregated misfolded monomers of IAPP.  
Amyloid deposits within pancreatic islets are a common feature of both T2D in people and FDM.  
Estimates suggest deposits of amyloid are found in greater than 90% of people and cats with 
diabetes mellitus.111-116 Additionally, islet amyloid can occasionally be found in apparently 
healthy adult and geriatric people and cats.   
The amyloidogenic potential of IAPP to misfold is largely determined by the amino acid 
sequence, but is also influenced by protein concentration, pH, associated stabilizing cations, and 
stabilizing chaperone proteins.18,117-120 Not all mammalian native IAPP peptides are able to 
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misfold into amyloid protein.  The peptide sequence between residues 25 and 29 appear to be 
particularly important, although sequence at the n-terminus of the peptide appear to also play a 
role.18 (Figure 1.7) Only people, non-human primates, and cats are known to spontaneously form 
pancreatic amyloid.  Mouse and rat IAPP is unable to form amyloid.  It is believed that the 
inclusion of multiple proline residues between residues 25 and 29 in rodent IAPP introduces 
rigidity to the tertiary structure that will not allow folding and formation of the quaternary 






Figure 1.7: The putative sequence of IAPP protein believed to be responsible for the 
protein’s ability to misfold is contained between residues 20-29.  The inclusion of several proline 
residues introduces rigidity to the tertiary structure of the peptide that inhibit misfolding.  Human 




Under normal conditions, IAPP monomers remain stable within the secretory granules.  
This stability is believed to be related to vesicular pH, crystal structure of insulin, and the 
presence of large quantities of Zn ions (millimolar concentrations within the vesicles).121,122 
Under certain conditions, IAPP molecules are able to misfold and will spontaneously 
form small-order multimers.  There is increasing evidence that these small oligomeric species of 
amyloid are quite toxic to the beta cell.123-127 The presence of oligomeric amyloid has been 
confirmed in beta cells of diabetic and non-diabetic people and in rodents transgenic for human 
IAPP.126,128 There are several hypotheses as to the nature of oligomeric amyloid toxicity to the 
beta cell.  Oligomeric amyloid is capable of inserting itself into lipid bilayers, creating pores and 
compromising the integrity of the membrane.125 The creation of such pores in the ER membrane, 
secretory vesicles, lysosomes, phagolysosomes, or cell membrane can have rapid and terminal 
effects on the cell.  Fresh human islets cultured in media seeded with supraphysiologic amounts 
of human IAPP had dramatic changes in morphology, increased apoptosis, and decreased insulin 
release.127  
IAPP misfolding and polymerization can propagate if not cleared by the cell, and 
extremely large and long fibrils of amyloid are formed.18 Fibrillar amyloid is deposited in the 
extracellular space and it is the collections of fibrillar amyloid that are visible microscopically.   
The presence of fibrillar amyloid in the diabetic and glucose competent cat is well 
documented.  What remains unknown is whether feline IAPP forms oligomers and whether these 
smaller misfolded proteins are associated with beta cell dysfunction in the cat as has been 
suggested in people.    
 1.6.5 Endoplasmic reticulum stress 
Post-translational processing of insulin and IAPP begins in the endoplasmic reticulum of 
beta cells.  Beta cells must remain highly labile and responsive to insulin demand and as such the 
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rate of synthesis of the beta cell varies hour to hour.  This rapid translation and variable demand 
makes the beta cells particular sensitive to accumulation of misfolded or incompletely folded 
protein in the ER.  The association of ER stress and beta cell dysfunction in people and rodents is 
well described in the literature.129-134 The unfolded protein response (UPR) is a mechanism by 
which cells are able to adapt to the volume of misfolded or unfolded proteins in the ER.  The 
effects of UPR activation include reduction of protein transcription and promotion and 
recruitment of chaperone proteins.  The UPR is highly adaptive and is largely regulated by three 
key proteins forming three canonical branches: protein kinase RNA-like endoplasmic reticulum 
kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 
(ATF6).135 PERK, IRE1 and ATF6 are all ER trans-membrane proteins and activation of these 
proteins is regulated primarily by association of the endoplasmic domain of the proteins with the 
chaperone protein Grp78 (also known as BiP).  Recruitment of Grp78 away from PERK, IRE1, or 
ATF6 during periods of high protein production or accumulation of misfolding proteins allows 






Figure 1.8:  There are three canonical branches of the UPR.  Accumulation of misfolded or 
unfolded proteins leads to disassociation of GRP78 from UPR mediating proteins, allowing 
dimerization and phosphorylation of IRE1 and PERK and phosphorylation of ATF6.  IRE1 
activation will in turn up-regulate the activity of XBP1s (not shown) which serves as a 
transcription factor to promote chaperone protein production (such as BiP).  Excessive activation 
of IRE1 also activates the JNK pathway leading to apoptosis.  PERK phosphorylates eIF2α which 
up regulates the activity of CHOP.  CHOP functions include induction of mitochondrial stress 
(and activation of the intrinsic pathway to apoptosis) and serving as a transcriptional regulator of 
several pro-inflammatory and pro-apoptotic products.  ATF6 phosphorylation allows for 
translocation of the cytoplasmic domain of the protein to the nucleus where it serves as a 
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transcription factor for, among other things, several chaperone and UPR-related proteins.  
Thapsigargin inhibits the function of the sarco/endoplasmic reticulum calcium ATPase (SERCA) 
pump, thereby depleting ER calcium stores.  Decreased ER calcium causes ER swelling and 
promotes misfolding while increasing cytoplasmic calcium leads to activation of the intrinsic 
apoptotic pathway.  Tunicamycin inhibits n-glycosylation of proteins, leading to misfolding and 
accumulation of these proteins within the ER.  GLP-1r signaling is anti-apoptotic via several 
mechanisms: direct inhibition of eIF2α, activation of the SERCA pump, inhibition of CHOP, and 







The primary downstream effects of PERK activation are mediated through eukaryotic 
translation initiation factor 2α (eIF2α).  eIF2α in turn functions to inhibit global protein 
transcription and relieve workload of the ER.  Excessive activation of eIF2α will also activate 
C/EBP homologous protein (CHOP) which is a potent transcription factor for various 
inflammatory and promotes pro-apoptotic pathways. 
Under mild ER stress, IRE1 phosphorylation results in ribonuclease activity of the 
cytoplasmic domain and cleavage of the X-box binding protein-1 (XBP1) mRNA, thereby 
generating an alternative, active transcript.  This spliced XBP1 in turn is a key promoter of 
chaperone proteins and phospholipid biosynthesis.  Excessive stimulation of IRE1 will also result 
in activation of cJun n-Terminal kinase (JNK) that will result in caspase activation and a pro-
apoptotic pathway.  IRE1 also promotes IκB kinase (IKK) degradation and activation of nuclear 
factor κB  (NFκB) which, as discussed later, can be both adaptive and mal-adaptive to the beta 
cell.   
The third major canonical branch is mediated through the translocation of the 
phosphorylated cytoplasmic domain of ATF6 which serves as a potent regulator of multiple ER 
stress associated products such as chaperone proteins and cAMP response elements.  As with the 
other branches, this regulation is adaptive under normal stimulation, but excessive stimulation 
will result in a pro-inflammatory, pro-apoptotic result. 
The negative effects of prolonged activation of the UPC in beta cells are well 
documented and, as mentioned in section 1.5.3, activation of the GLP-1 receptor has been shown 
to modify the beta cell response to ER stress.53,136-139 In both in vivo and in vitro experiments in 
rodents as well as cell culture experiments using human tissues treatment with GLP-1 or GLP-1 
mimetics resulted in attenuation of the UPC in beta cells resulting in improved secretory capacity, 
33 
 
decreased rate of apoptosis, and down-regulation of components of the UPR after treatment with 
GLP-1 or GLP-1 mimetics. 
 
 1.6.6 Inflammation 
The term “insulinitis” is used to describe inflammation associated with pancreatic islets.  
In the case of human type-1 diabetics, inflammation in response to immune-mediated signals is 
characterized by cellular infiltrates and a cytotoxic immune response directed against the beta 
cells.  In Type 2 diabetic people, there is an increasing body of evidence supporting the role of 
inflammatory cytokine involvement in beta cell dysfunction and induction of apoptosis.140-142 The 
insulinitis hypothesis centers around the pro-inflammatory cytokine IL-1β.  Pancreatic beta cells 
express both IL-1β and the IL-1β receptor.141,143 Multiple experiments originating from the same 
research group have demonstrated that increased glucose concentrations are associated with up-
regulation of IL-1β and the autocrine and paracrine effects of IL-1β are major contributors to beta 
cell loss of function and apoptosis.143-146 The importance of endogenously produced IL-1β is 
highlighted by the finding that the addition of an IL-1β receptor antagonist which protected beta 
cells from apoptosis when exposed to high glucose concentrations in culture.143 Exposure of 
isolated rodent and human islet cells to IL-1β alone is also well described to induce beta cell 
apoptosis.  
The role of IL-1β in progression of beta cell dysfunction is also suggested by several 
clinical trials using the IL-1R antagonist anakinra (Kineret®) which demonstrated utility of the 
drug by improving insulin responsiveness to glucose in pre-diabetic and Type 2 diabetic 
people.147-150 These clinical findings are consistent with experiments using isolated human islets 
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and rat beta cells in which IL-1β receptor blockade with anakinra protects cells from pro-
inflammatory cytokine induced necrosis and apoptosis.    
The insulinitis hypothesis and the role of IL-1β is not universally accepted and there are 
conflicting experiments in the literature.  Other research groups have been unable to detect IL-1β 
production in rat islets or in islets from pre-diabetic sand rats.151 In a 2005 paper, islets harvested 
from non-diabetic human donors were cultured under high and low glucose concentrations, with 
and without IL-1R antagonists.152 Islets were also harvested from Type 2 diabetic people and 
expression of IL-1β and NFκB was measured.  The investigators concluded that the lack of 
correlation of IL-1β or NFκB to any changes associated with hyperglycemia or diabetes made it 
“unlikely that locally produced IL-1β is an important mediator of glucotoxicity to human islets 
and argues against the IL-1β/NFκB pathway as a common mediator for beta cell death in type 1 
and type 2 diabetes.”152 Furthermore, the authors of a recent study using mouse islets concluded 
that beta cell apoptosis secondary to increased glucose or ER stress did not involve the NLRP3 
inflammasome (and consequently IL-1β), and IL-1β knockout conferred no protection in 
response to glucotoxicity.153 
There is no singular reason for such startling contradictions in the literature regarding the 
role of IL-1β in beta cell dysfunction.  Undoubtedly part of the answer lies in the complexity of 
inflammatory cytokine signaling and beta cell response to acute and chronic nutritional changes.  
Minor stimulation of IL-1β, by activation of NF-κB, will promote pro-survival, pro-proliferative, 
and anti-apoptotic stimuli whereas chronic or excessive activation of NF-κB by IL-1β will drive 
signaling along a pro-apoptotic path.   
The concentration of IL-1β that pancreatic beta cells are typically exposed to in vivo is 
not known.  The IL-1 receptor is a high-affinity receptor and presumably biologic effects will be 
seen at doses well below the disassociation constant of the receptor.141,154 Freshly isolated human 
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islets were reported by one group to produce a mean of 4.0pg/ml IL-1β after culture for 48 hours 
under baseline glucose concentrations.155 This is in stark contrast to the 500-1000 fold higher 
concentrations (2-4ng/ml) of IL-1β used to induce beta cell apoptosis in other experiments.143,156 
There also appears to be a species difference in the susceptibility of pancreatic beta cells to the 
negative effects of IL-1β, with mice being relatively resistant to the effects while cows and rats 
are relatively sensitive and human islets have been reported as both very sensitive and very 
resistant to the effects of IL-1β.154,157 
The duality of IL-1β signaling on beta cells was recently described in experiments using 
rat beta cells and freshly isolated human islets.  In both rat and human tissues, exposure to low 
concentrations of IL-1β (10-100pg/ml) enhanced insulin production whereas exposure to high 
concentrations of IL-1β (20,000pg/ml) caused a marked decrease in insulin production.158   
The role of inflammatory cytokine expression in feline beta cells has not been fully 
explored. It has been documented that feline beta cells express the IL-1β gene and that IL-1β 
mRNA increases after challenge with LPS in freshly isolated feline islet-like clusters.159 
However, in a separate study of cats after a 10 day hyperglycemic clamp, inflammatory cytokine 
(IL-1β, TNF-α, IL-6, IL-8, and monocyte chemoattractant protein-1) mRNA expression in 
isolated islet-like clusters remained unchanged despite a 4-fold decrease in insulin mRNA and 
profound overall loss of beta cell mass confirmed histologically.78 Further work is needed to 
determine the relative sensitivity of feline beta cells to IL-1β.  
 
1.7 In vitro methods to study beta cell function 
Because of the complex nature of the disease, studying diabetes mellitus in vivo is 
exceptionally complicated.  As has been outlined, adiposity, local and systemic inflammation, 
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peripheral insulin sensitivity, diet, background genetics, and redox state have all been shown to 
have a role in the development of clinical feline diabetes.  Beta cell function and dysfunction is 
often inferred by evaluating the changes in secretory patterns of the beta cells (e.g. alterations of 
plasma insulin or IAPP), clinical signs (e.g. glycemic status or change in body weight), or in post-
mortem evaluation of tissues taken after disease state is achieved.  In vitro experiments using 
isolated islet tissue clearly have benefit because they allow for greater control and investigation of 
specific pathways involved in disease development unique to the environment of the pancreatic 
islet. 
In vitro study of disease pathogenesis is complicated by the lack of fully physiologically 
competent cell lines that can be immortalized in culture.  The majority of cell lines used in 
diabetes research are rodent insulinoma lines produced as either transgenic or radiation induced 
cells (including INS-1, RINm5F, and MIN6).  There is at least one human insulinoma cell line 
cultured from metastatic carcinoma cells collected from a single patient (CM cell line).   
Unfortunately, none of the available cell lines are physiologically normal in their ability to 
produce insulin, their response to glucose, or their expression of glucose transporters.  There are 
currently no immortalized cell lines from the cat available for study. 
The exocrine pancreas is rich in digestive enzymes such as lipase and amylase, which can 
be very damaging and detrimental to tissue stability once in culture and thus represent a 
significant hurdle to using whole-organ explant or transplant for in vitro study.  Intact pancreatic 
islets provide a good alternative because, although technically challenging to isolate, they allow a 
complete separation from the exocrine pancreatic tissue while providing a complex environment 
of multiple cell types, each with significant paracrine effects on its surrounding cells.  
Maintaining cell-cell interactions and paracrine signaling allows for a more physiologic response 
of the beta cells to manipulation.   
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Primary cell culture from people or rodents is commonly used for in vitro study of 
disease mechanisms.  Techniques for the liberation and purification of intact islets or individual 
beta cells are well established for these species.  Most protocols rely on collagenase-based tissue 
digestion to liberate islets and, if desired, trypsin dispersion of the islet to individual cells to 
isolate the beta cells.  Once isolated, islet tissue can either be stained by the zinc chelating dye 
dithizone (which turns zinc-rich beta cells a bright red color) and hand-picked for purity, or can 
be separated using density gradient centrifugation.160 The latter is the method most commonly 
utilized in rodents and pigs.161-164 
There have been two attempts documented in the literature to produce purified feline 
islets for laboratory study or tissue transplant.  In the first published experiments, feline pancreata 
from cadaveric donor cats were subjected to collagenase digestion and the resulting digestate was 
cultured in enriched media.165 Although there was some manual selection for “exocrine free” 
islet-like clusters, significant exocrine tissue still remained.  The yield of islet clusters free of 
exocrine tissue was estimated to be 300-500 islets per cat.  Additionally, the whole pancreatic 
digestate was allowed to rest in culture media for a period of 1-9 days.  The estimated percentage 
of insulin positive cells in this milieu was never higher than 5%.  Islets of cats should contain at 
least 60% beta cells, and so these results suggest that either the resulting digestate contained 
significant amounts of exocrine tissue or isolation resulted in the loss of more than 80% of islet 
beta cells.  Investigators in this study also noted that although the “islet like clusters (ICCs)” 
attained a more uniform shape over the 9-day period, there was a decreasing amount of insulin 
positive tissue and much of the remaining tissue was proliferating ductal epithelium.  ICCs 
transplanted into recipient cats underwent rapid rejection and none of the cats experienced more 
than 12 days of normoglycemia and life expectancy did not exceed 27 days.   
This study had several limitations, the most significant of which was the lack of purified 
islets that retained some degree of normal secretory function.  The failure of collagenase 
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digestion to yield large quantities of islets clean of exocrine tissue was briefly investigated.  
Electron microscopic findings suggested that most of the islet tissue was closely associated with 
the surrounding acinar tissue, with little to no collagenous connective tissue between them.  It 
was postulated that the lack of connective tissue was the most likely reason for a failure of 
collagenase digestion to produce clean islet tissue.  Unfortunately, in the unpurified tissue (whole 
digestate) the authors failed to yield any number of apparently pure or functional islets.  The 
investigators transplanted between 3,500 and 23,000 of these impure “ICCs” into the sub-retinal 
space of cats.  It is therefore not surprising that there was an unimpressive clinical response and 
rapid failure of the tissue grafts.    
The second set of documented experiments to produce purified islets from the cat met 
with similar success in regards to yield of purified islets.166 In this experiment, six collagenase-
based methods for islet isolation were compared.  The differences between protocols included 
second course collagenase digestion, ficoll gradient purification, and use of a second enzyme 
(Accutase®) to attempt to disperse islets more efficiently.  Digestion with collagenase yielded 
large quantities of islets still embedded within exocrine tissue with approximately 2% of islets 
identified as “free”.  None of the six methods produced any significant increase over another 
regarding volume of purified islets.  Islets harvested in these experiments were not cultured and 
their secretory capacity was not evaluated.   
 
1.8 Treatment of feline diabetes mellitus 
 1.8.1 Insulin 
Standard therapy of feline diabetes has two main arms, both of which focus on returning 
the patient to euglycemia.  First, insulin hormone must be replaced to lower blood glucose.  This 
is typically accomplished via administration of parenteral insulin.  Secondly, insulin sensitivity of 
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tissues must be improved to reduce the demand on an already failing beta cell population.  To this 
end, weight loss to restore insulin sensitivity and insulin sensitizing medications can be 
employed. 
It is commonly accepted that most newly diagnosed, hyperglycemic diabetic cats (similar 
to Type 2 diabetic people) have some degree of residual beta cell function remaining at the time 
of diagnosis.  For many of the reasons discussed above, loss of beta cell function and 
development of peripheral insulin resistance is a gradual process.  This fact has led to significant 
interest directed towards therapies that can help restore functional beta cell mass and improve 
peripheral insulin resistance.  The goal is to return the patient to euglycemia without the need for 
parenteral insulin, a state termed “diabetic remission.”  This definition acknowledges that while 
the patient is not considered “normal” or permanently glucose competent, they do not currently 
require insulin therapy. 
Aggressive insulin therapy and tight regulation of euglycemia is associated with an 
overall diabetic remission rate of 64%.167 It is believed that the reduced glycemic load reverses 
the effects of glucotoxicity and allows the beta cells of the pancreas to recover.  The concept that 
beta cell “recovery” is possible after extended hyperglycemia and documented beta cell 
dysfunction was demonstrated in a 2013 study.168 In this experiment, cats were clamped at a high 
serum glucose concentration (30mMol) for a period of 42 days. During this time, endogenous 
insulin production was initially increased but quickly decreased to the lower limit of detection for 
the duration of the study.  Biopsy samples taken at the end of the hyperglycemic period 
confirmed wide-spread destruction of islet tissue in all cats and loss of insulin-positive beta cells 
positive for insulin using immunohistochemical stains.  Six of 16 cats were treated with insulin 
during the hyperglycemic clamp to avoid ketoacidosis.  However, once the infusion of glucose 
was discontinued, 10 of 16 cats required no parenteral insulin to maintain euglycemia and insulin 
40 
 
therapy was discontinued in the remaining 6 cats within the following two weeks.  After a 21-day 
“recovery” period, all cats were able to maintain euglycemia without any medications.   
 
 1.8.2 Incretin mimetics 
Significant potential exists for the treatment of feline diabetes mellitus with incretin 
mimetics.169 As previously outlined, incretins and various mimetic drugs (most notably exendin-
4) have been documented to induce satiety, promote weight loss, increase beta cell 
responsiveness to glucose, rescue beta cells from oxidative damage, and restore depleted beta cell 
mass in rodents and in people.  The theoretical benefits in the cat cannot be overstated if each of 
these findings translated clinically to treatment of the feline diabetic.   
There are two fundamental approaches to incretin therapy.  One approach is to inhibit 
degradation of GLP-1 and GIP by inhibiting the DPP-4 enzyme.  The second approach utilizes 
synthetic compounds with similar affinity for the GLP-1 receptor but that are resistant to DPP-4 
activity. (Figure 1.9)  To date, two GLP-1 mimetics (exenatide and liraglutide) and two DPP-4 
inhibitors (sitagliptin and NVP-DPP728) have been investigated in cats. Exenatide short acting 
(Byetta®, Amylin Pharma) has been evaluated by two research groups and in both cases it was 
found to have a dose dependent insulinotropic effects in healthy cats with no reported severe 
adverse events associated with the drug.170, 171 Only one study describes chronic administration of 
exenatide and the drug was not associated with adverse events, although weight loss was 






Figure 1.9: (A) Sequence for human GLP-1.  The sequence for feline GLP-1 has not been 
determined.  (B) Exendin-4 (exenatide) shares only 35% homology with GLP-1 but the 
substitution at position 2 of glycine for alanine confers resistance to DPP4 degradation.  (C) 
Liraglutide shares near 100% sequence homology to native GLP-1, but the addition of a 16-
carbon fatty acid side chain allows for binding to albumin and protects the hormone from 







There are two recent publications evaluating the pharmacokinetics and 
pharmacodynamics of long-acting exenatide (Bydureon®, Amylin Pharma).172,173 Exenatide 
extended release was documented to have insulinotropic effects at least three weeks after initial 
injection with a peak in plasma concentration of the drug seen at four weeks post injection with 
no adverse events noted.173 In another study, exenatide long-acting was compared to exenatide 
short-acting.  In this study, exenatide short acting was associated with a more robust effect on 
insulin release.  Exenatide short-acting was associated with an increased insulin area under the 
curve of between 320 and 540% as compared to 95-178% for exenatide long-acting.    
Liraglutide (Victoza®, NovoNordisk) was recently investigated as a once daily drug in 
cats.174 Over a 14 day study period, liraglutide was shown to significantly increase insulin 
concentrations during hyperglycemic clamp while also decreasing glucagon concentrations.  
Liraglutide was also associated with a significant reduction in weight and appetite. 
Only one oral DPP-4 inhibitor, sitagliptin (Januvia®, Merck) has been investigated to 
date in cats.  In one report, sitagliptin provided a modest increase in post-prandial serum insulin 
which is in contradiction to a second report in which no effect of sitagliptin on post-prandial 
insulin was detected.172,175 NVP-DPP728 is a small molecule inhibitor of the DPP-4 enzyme that 
must be administered intravenously.  It has been evaluated in one study where it was given to 
apparently healthy cats.176 Single dose of NVP-DPP728 was effective at reducing plasma 
glucagon and increasing plasma insulin in response to a meal.  NVP-DPP728 is only available for 
biochemical research and there are no known plans to develop this compound as a drug for use in 
the clinical setting. 
Our expectations for these drugs to be effective in our feline patients are rooted in the 
inherent similarities between feline diabetes and Type 2 diabetes in people, in whom incretin-
based therapies are commonly used.  There are still significant gaps in our knowledge of the 
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cellular and molecular basis for disease in the cat and it is unknown if incretin therapies will have 
similar effects on the feline beta cell as have been described in other species.   
 
1.9 Summary and statement of hypothesis 
In order to better understand the development of beta cell dysfunction in diabetics and the 
role of GLP-1 and GLP-1 mimetics in mitigating these changes, we developed the following 
central hypothesis: 
GLP-1 and GLP-1 mimetics have a beta cell sparing effect in feline pancreatic islets 
by mitigating the dysfunction associated with amyloid, oxidative stress, inflammatory 
cytokine signaling, and endoplasmic reticulum stress thereby inhibiting cell death. 
It is well documented that pancreatic islets from people and rodents have evidence of 
oxidative stress and inflammatory cytokine signaling associated with exposure to conditions 
similar to that seen in the developing diabetic, namely hyperglycemia.  It is unknown if these 
same changes are found in the diabetic cat.  We hypothesized that the pancreatic islets of 
diabetic cats will have evidence of increased oxidative modification, inflammatory cytokine 
signaling and amyloid as compared to control cats. In order to test this hypothesis we 
established the following aim:  
Aim 1: Characterize the markers of inflammation, oxidative stress, and amyloid 
in the pancreatic islets of normal and diabetic cats.  To achieve this aim, 
histologic samples from control and diabetic cats were obtained and semi-




Efforts to study mechanisms of beta cell dysfunction in the cat are severely hampered by 
the lack of available techniques to isolate and culture feline islet tissue in vitro.  We hypothesized 
that feline pancreatic islets can be isolated and maintained in culture without loss of function 
for a period of two days and with good viability for a period of five days.  In order to test this 
hypothesis we established the following aim: 
Aim 2: Develop a technique for the isolation and culture of purified feline 
pancreatic islets suitable for use in functional assays.  To achieve this aim, islets 
from cadaveric cats were isolated using collagenase-based digestion and 
maintained in culture for a period of 2-5 days.  Viability was estimated by 
fluorescent assay and quantified by LDH release into the media.  Islets were 
subjected to a glucose stimulated insulin production and release assay after two 
days in culture. 
The extremely high demand on beta cell synthesis of proteins (insulin and IAPP) make 
the pancreatic beta cells particularly susceptible endoplasmic reticulum stress secondary to 
protein misfolding.  We hypothesized that exenatide will reduce ER stress-related activation of 
apoptosis in pancreatic islets exposed to ER stress.  In order to test this hypothesis, we 
established the following aim: 
Aim 3: Determine the effect of increased ER stress on caspase 3 activity in 
freshly isolated islets.  To accomplish this aim, freshly isolated feline islets were 
exposed to drugs inducing ER stress and caspase 3 activity was quantified. 
Aim 4: Evaluate the effects of the GLP-1 mimetic exenatide on caspase activity 
of freshly isolated islets under conditions of ER stress.  To address this aim, 
doses of drugs identified in Aim 3 were used to induce ER stress and thereby 
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caspase 3 activity in islets.  The treatment effect of co-culture with exenatide and 
ER stress drug on caspase 3 activity was then quantified. 
Finally, the clinical application of the GLP-1 mimetic exenatide was evaluated in newly 
diagnosed diabetic cats.  The benefits of GLP-1 mimetics in human diabetics are well described 
and the many similarities between feline and human Type 2 diabetes led us to the hypothesis that 
the addition of exenatide to standard insulin therapy will be associated with better glycemic 
control of newly diagnosed feline diabetics.  In order to test this hypothesis, we developed the 
following aims. 
Aim 5: Evaluate the effects of adjunctive therapy with exenatide in addition to 
exogenous insulin in newly diagnosed feline diabetics.  To investigate this aim, 
we recruited newly diagnosed feline diabetics presented to the Boren Veterinary 
Medical Teaching Hospital.  A double-blind, placebo-controlled study design 
was used and patients were either treated with insulin alone or in combination 
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The pathogenesis of beta cell dysfunction leading to pancreatic beta cell failure seen in type 2 
diabetes mellitus is incompletely understood.  Pancreatic tissues were collected from nine control 
cats and nine diabetic cats and stained using immunohistochemical methods for interleukin-1β 
(IL-1β), insulin, islet amyloid polypeptide (IAPP), and 4-hydroxynonenal (4-HNE).  Thioflavin-S 
was used to stain for amyloid deposits.  All control cats showed positive staining for IL-1β and 4-
HNE.  Diabetic cats showed varying degrees of staining for inflammation and oxidative 
modification, owing in large part to the very small amount of islet structure remaining in the 
typical diabetic cat.  Amyloid deposition was identified in 8/9 diabetic cats and 1/9 control cats.  
In order to validate our findings of oxidative modification and inflammatory cytokine signaling in 
the control pancreases, paired biopsy samples taken (baseline and after 8-16 weeks of obesity and 
hyperglycemia) from an additional group of cats enrolled in an obesity and hyperglycemia study 
were stained for IL-1β and 4-HNE.  A similar pattern of staining was identified in the baseline 
samples as seen in control cats.  A significant increase in IL-1β and 4-HNE staining was seen 
after a period of hyperglycemia and obesity.  Taken together, these findings suggest that while 
present in normal cats, markers of inflammation and oxidative modification increase very early 
on during the development of disease.  Future studies focusing on these earlier time-points are 
needed to understand the factors that function in protection of the islet beta cell and the 
development of islet pathology in Type 2 diabetes mellitus in the cat.  
 
Introduction 
It is estimated that Type 2 diabetes mellitus (T2D) will affect nearly one in three adults in the 
United States of America by the year 2050 according to one study (Boyle et al., 2010).  The 
domestic feline population has undergone a similarly remarkable increase in morbidity from this 
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disease.  It was estimated that the incidence of T2D in cats was 0.08% in 1970, but by recent 
accounts is now estimated to be as high as 1.2% (Prahl et al., 2007; Rieder et al., 2008). 
 
The pathogenesis of beta cell dysfunction and failure resulting in T2D is incompletely 
understood.  It is clear that development of disease is not the result of any single mechanism.  By 
the time clinical signs of T2D are manifested, the underlying pathologic processes have been 
developing for weeks, months, or even years.  Diet, genetics, activity, obesity, and environment 
as well as cellular processes such as accumulation of oxidative damage, inflammation, and 
misfolded proteins interact, ultimately resulting in a loss of functional beta cell mass and overt 
hyperglycemia (Boni-Schnetzler et al., 2008; O'Brien, 2002). 
 
Insulin demand is dictated by peripheral insulin sensitivity, dietary glucose intake, and 
gluconeogenic mechanisms.  The early stages of T2D are characterized by relative compensatory 
hyperinsulinemia in response to peripheral insulin resistance.  At some point, the insulin 
producing capacity of the beta cell is exhausted and a permanent relative or absolute 
hypoinsulinemic state develops.  
 
Aside from insulin, the other major secretory product of pancreatic beta cells is islet amyloid 
polypeptide (IAPP), also known as amylin.  In health, IAPP is stored in secretory granules at a 
1:50 molar ratio to insulin (Westermark et al., 2011).  During periods of hyperinsulinemia there is 
a concurrent rise of circulating IAPP and it has been reported that the serum ratio of IAPP to 
insulin changes with disease (Gasa et al., 2001; Lutz and Rand, 1996; Mulder et al., 1995; 




In the vast majority of spontaneous T2D in humans and cats, IAPP-derived amyloid is deposited 
within the islet structures (Johnson et al., 1989; O'Brien et al., 1986).  The presence of islet 
associated amyloid deposits is associated with a loss of beta cell mass and loss of insulin 
secretion by the pancreas (Höppener et al., 2002; Lutz and Rand, 1997). 
 
Reactive oxygen species are produced as the result of normal aerobic metabolic processes and 
there is a constant interplay between oxidative and antioxidant forces in the cell.  It has been 
demonstrated that diabetic people have evidence of increased oxidative stress both systemically 
and locally, and it is believed that oxidative stress is involved in the process of beta cell 
dysfunction and apoptosis (Acharya and Ghaskadbi, 2010; Bast et al., 2002; Ihara et al., 1999; Li 
et al., 2009; Modak et al., 2011; Robertson et al., 2004).   
 
Pro-inflammatory cytokine signaling has also been implicated as a central player in the initial 
maintenance and ultimate destruction of the pancreatic beta cell.  It has been proposed that 
interleukin-1β (IL-1β) signaling is useful in stimulating pro-survival signals through promotion of 
NF-kB signaling.  Through autocrine feedback, prolonged IL-1β signaling eventually pushes the 
cell in a pro-apoptotic direction and may ultimately be partly responsible for loss of beta cell 
mass (Boni-Schnetzler et al., 2008).  The importance of IL-1β signaling is supported by a clinical 
study of an IL-1β receptor antagonist that resulted in improved beta cell survival, insulin 




The aim of this study was to characterize markers of oxidative modification, inflammation, and 
amyloid within the pancreatic islets of normal and diabetic cats.  Immunohistochemical and 
fluorescent staining techniques were employed to detect markers of inflammation (IL-1β, 
interleukin-6 (IL-6)), markers of oxidative modification (4-hydroxynonenal (4-HNE)), insulin, 
IAPP, and amyloid.  We hypothesize that the islets of diabetic cats will contain evidence of 
increased oxidative modification, increased inflammation, and amyloid accumulation as 
compared to islets of normal cats.   
 
Materials and Methods: 
 
Case selection: 
Cases of spontaneous diabetes mellitus in cats were identified by reviewing the submission 
records to the Oklahoma Animal Disease Diagnostic Laboratory in Stillwater, Oklahoma.  A 
diagnosis of diabetes mellitus characterized by spontaneous and persistent hyperglycemia made 
by the submitting veterinarian and sufficient paraffin embedded tissue available for stains were 
considered adequate for inclusion into this study.   Cases with severe systemic disease such as 
fungal infection or sepsis were excluded.  Additionally, histologic evidence of severe acute or 
chronic pancreatitis resulted in exclusion of that individual.  Nine cases met inclusion criteria for 
the diabetic group.  A summary of signalment, cause of death, and if available, duration of 
disease is included in Table 1. 
 
A group of apparently healthy research cats (n=4) enrolled in an unrelated study were evaluated 
before and after induction of obesity and hyperglycemia to serve as an additional control group.  
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Paired, surgical biopsy samples were taken from individuals at the time of enrollment and again 
after the cats had been maintained obese and hyperglycemic for a period of time (8-16 weeks).   
 
Pancreases were collected from apparently healthy cats (n=9) killed as a part of routine 
population control from a local animal shelter.  Cats were deemed apparently healthy by shelter 
staff and showed no signs of respiratory, dermatologic, or neurologic disease during the time they 
were observed at the shelter.  Pregnant individuals were excluded.  No exclusions were made 
based on age or gender.  Hematoxylin and eosin stained sections of pancreatic tissue from each 
case were reviewed by a board certified pathologist.  Any evidence of acute or chronic 
pancreatitis resulted in exclusion from the normal study group.   
 
The samples utilized in this study were from various locations within the pancreas.  Previous 
publications have demonstrated that there is a fairly homogenous distribution of islets within the 
feline pancreas and so no attempts were made to try to localize the origin of the sample (Lutz et 
al., 1994a; O'Brien et al., 1993). 
 
Histologic evaluation: 
Hematoxylin and eosin stained 4-micron sections of pancreas were examined by a board certified 





Sections were re-hydrated by first processing in xylene followed by decreasing ethanol 
concentrations and finally distilled water. Endogenous peroxide activity was blocked using a 3% 
hydrogen peroxide bath.   
 
For immunohistochemical staining for IL-1β, 4-HNE, IL-6, IAPP, and insulin, sections were 
processed using heat induced epitope retrieval.  Sections were treated for 15 min at 95°C in a 
citrate buffered solution (10mM, pH6.0).  After 15 min, sections were allowed to gradually cool 
down for an additional 15 min in the buffer solution before bringing to room temperature in 
phosphate-buffered saline solution (PBS).  Sections were then incubated for 20min in 10% 
normal blocking serum from the species in which the secondary antibody was raised. 
  
Working concentrations of primary and secondary antibodies were optimized and appropriate 
negative controls were performed.  For negative controls, samples were processed the same as all 
other samples with the exclusion of the primary antibody.  Additional negative controls were 
conducted for IL-1β, IAPP, and insulin by pre-incubating the primary antibody with the target 
peptide for 12 hours prior to application of the primary antibody and processing of the sample as 
described.  Primary antibody working concentrations were as follows: anti-feline IAPP antibody 
(Bachem, Torrance, CA, USA) 1:600, anti-feline insulin antibody (Cell Signaling, Danvers, MA, 
USA) 1:500, anti-feline IL-1β antibody (R&D Systems, Minneapolis, MN, USA)  2ug/ml, anti-
feline IL-6 (R&D Systems, Minneapolis, MN, USA) 6ug/ml, anti-4-HNE antibody (Millipore, 




Samples incubated with anti-IL-1β, IL-6, insulin, and IAPP were incubated with primary 
antibody overnight at 4°C.  Samples for 4-HNE were incubated with primary antibody for one 
hour at room temperature.  Secondary antibodies directed to the primary antibody (Vector 
Laboratories, Burlingame, CA, USA) were incubated for one hour at room temperature.  A 
streptavidin amplification step (Vectastain ABC, Vector Laboratories, Burlingame, CA, USA) 
was utilized and chromogens (Immpress Novared and DAB, Vector laboratories, Burlingame, 
CA, USA) were used as indicators.   
 
Digital images were scanned using a digital microscope system (Aperio ScanScope CS2, Leica 
Biosystems, Nussloch, Germany).  Snapshots of higher magnification images were captured using 
image software (Aperio ImageScope, Leica Biosystems, Nussloch, Germany).  For calculation on 
insulin and IAPP staining, the entire area of pancreas visible on the section was captured as 10x 
snapshots (average 10 images) were then used in image processing and quantification.  For 
calculation of 4-HNE and IL-1β, 40x snapshots of between 10 and 20 morphologically 




After re-hydration as described above, sections were incubated for one minute at room 
temperature in a solution of 1.0% thioflavin-S (Sigma Aldrich, Saint Louis, MO, USA) in PBS.  
Sections were rinsed briefly three times in 70% ethanol and then in distilled water.  Coverslips 
were mounted using glycerin jelly.  Sections were examined using a Nikon Eclipse 50i 
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microscope at an excitation wavelength of 450-490nm, and an emission wavelength of 495nm.  
Images were taken using a Nikon Digital Sight DS-L1 camera. 
 
Image processing and staining quantification: 
All images were processed using a software program (ImageJ, NIH, Bethesda, MD, USA) and 
quantified by one observer (AMH) who was masked to sample identity.  Quantification of IAPP, 
insulin, and thioflavin-S, was accomplished using the software program and the following 
procedure:  Briefly, all non-parenchymal areas of the image were trimmed away and the area of 
pancreas was calculated using calibrated measurements.  Images were then converted to a 32-bit 
grayscale image and the “threshold” function was used to filter out areas of non-staining or 
insufficient staining intensity.  The results are reported as a ratio of positive staining per total 
area of pancreas measured. 
 
To quantify intensity of staining of 4-HNE and IL-1β the surface area of individual islets captured 
was calculated and the same techniques of grayscale conversion and image thresholding were 
used to calculate the proportion staining positive for 4-HNE or IL-1β.  The results are reported as 
a ratio of positive staining per islet in the sample.   
 
Statistical Analysis 
Differences between groups were evaluated using a software program (GraphPad Prism, 
GraphPad Software, Inc, LaJolla, CA, USA).  Non-normally distributed data was transformed 
using negative natural log.  Log-transformed and normally distributed variables (insulin, IAPP, 
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IL-1β, 4-HNE) were compared using a Student’s t-test.  Non-normally distributed data 
(thioflavin-T) was compared using a Mann-Whitney U test.  Differences were considered 
significant when the calculated p-value was <0.05. 
 
Results: 
Hematoxylin and eosin stain: 
A representative image of an islet from the control group is seen in Figure 2.1A.  Histopathologic 
changes were found in only one control cat and included deposition of amorphous, eosinophilic 
material effacing occasional islets (amyloid).  
 
Common histopathologic findings in the H&E stained pancreas sections in the diabetic group 
included nodular exocrine pancreatic hyperplasia, vacuolated islets, lack of morphologically 
identifiable islets, and amorphous, eosinophilic material effacing islets (amyloid) (Fig. 2.1B). 
 
Insulin 
Representative images of pancreas stained for insulin are seen in Figures 2.2A-B.  Insulin staining 
was significantly reduced in the diabetic group compared to control (p<0.0001), with a mean ratio 
of 0.0253 (range 0.00083-0.0843 insulin positive/total pancreas area) in the diabetic cats and 
0.4195 (range 0.2813-0.5425 insulin positive/total pancreas area) in the control cats (Fig. 2.2C).  
Cells staining positive for insulin were nearly all associated with a morphologically identifiable 
islet in the normal group and in most of the diabetic group (Fig. 2.2A).  In the diabetic group it 
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was also common to see individual or small clusters of cells staining positive for insulin outside 
of any identifiable islet (Fig. 2B).   
 
IAPP 
Representative images stained for IAPP are seen in Figures 2.3A-B.  The antibody for IAPP 
recognized both unfolded, native IAPP within the beta cell and the fibrillar amyloid deposited in 
the tissues around the beta cell.  Therefore, the proportion of pancreas staining positive for IAPP 
varied greatly depending on the presence or absence of amyloid within the islet, with a mean 
IAPP/pancreas area of 0.0558 (range 0.00115-0.2596) in diabetic cats and 0.01367 (range 0.0106-
0.0207) in the control cats (p=0.53).  In the normal cats, IAPP staining was localized to the islet 
beta cells.  When amyloid was present, the IAPP antibody produced a diffuse darkening of the 
amyloid deposits but never with the intensity associated with the staining of a beta cell containing 
native IAPP.   
 
Thioflavin-S 
Deposits of amyloid could be easily identified (Fig. 2.4A-B).  The presence of mild background 
fluorescence did not affect the detection of positive signal or affect calculations using the image 
software.  The mean proportion of pancreatic area staining positive with thioflavin-S was greater 
in diabetic cats (p=0.001) with a mean ratio of 0.03111 (range 0.0 to 0.075) in diabetic cats and 





Representative images stained for IL-1β are seen in Figures 2.5A-B.  Positive staining for IL-1β 
was found in nearly all islets.  In normal islets, the IL-1β staining was limited to cells around the 
periphery of the islet consistent with beta cells (Fig. 2.5A).  In diabetic cats, IL-1β staining was 
found in cells associated with vacuolated islet structures (Fig. 2.5B).  We were not able to 
confirm the identity of these cells (mononuclear cell or beta cell).  There was significantly less 
staining for IL-1β in diabetic cats with a mean proportion of positive staining per islet area of 
0.0754 (range 0.0097-0.311) in diabetic cats and 0.35 (range 0.174-0.573) in control cats 
(p<0.001. Fig. 5F). 
 
IL-6 
In order to confirm the presence of inflammatory cytokine signaling within the islet, sections of 
pancreas from a subset of cats in each group were randomly selected and stained for IL-6.  
Similar to IL-1 β, IL-6 staining was found in nearly all islets.  In normal islets, IL-6 was localized 
in anatomically identical islet location presumed to be beta cells (Fig. 2.5H). 
 
4-Hydroxynonenal 
Representative images stained for 4-HNE are presented in Figures 2.6A-E and 2.6G.  4-HNE 
staining was found in islets from nearly all cats.  There was significantly less staining for 4-HNE 
in diabetic cats with a mean proportion of islet staining positive for 4-HNE of 0.236 (range 0.04-
0.67) in diabetic cats and 0.4127 (range 0.235-0.555) in control cats (p=0.05).  Staining for 4-
HNE was strongest in the islet periphery in the region of the beta cells and in association with 




Additional control group 
The finding of large amounts of inflammatory cytokines and oxidative modification in the islets 
of normal cats was unanticipated.  Since these control cats were all sourced from a shelter and 
had unknown extended medical histories it is possible the control cats were not truly normal.  
Furthermore all samples in this study were collected from individual animals at postmortem 
examination resulting in marked inter-animal variation.  Tissues from the cats prior to induction 
of obesity and hyperglycemia (baseline) also showed extensive positive staining for inflammatory 
cytokines and oxidative modification (Figs 2.5C-D, and 2.6D-E).  Paired samples from the study 
endpoint (post) showed a significant increase in both IL-1 β (p=0.004) and 4-HNE (p=0.006) 
staining in islets from the same individual after a period of obesity and hyperglycemia (Figs. 
2.5G, 2.6F). 
 
To explore the possibility that oxidative modification and inflammatory cytokine staining was a 
phenomenon of older cats, the pancreas of a kitten approximately 4 months of age was stained for 
IL-1β and 4-HNE.  These sections demonstrate a similar, although less intense, pattern of positive 
staining (Figs. 2.5E and 2.6G). 
 
Discussion: 
The aim of this study was to characterize markers of oxidative modification, inflammation, and 
amyloid within the pancreatic islets of normal and diabetic cats in order to identify potential 




One of the interesting findings from this study was the evidence of both oxidative modification 
and inflammatory cytokines in the islets of normal individuals.  Oxidative modification is 
associated with an imbalance in the production of reactive oxygen species (ROS) such as nitric 
oxide, hydroxide ion, peroxide, and superoxide, relative to the anti-oxidant capacity of the cell.  
ROS are normally produced as a by-product of many different cell functions.  However, in states 
of increased inflammation or metabolic derangements, the production of ROS can exceed the 
anti-oxidant capacity of the cell.  The resulting excess free radicals produced can react with a 
variety of lipids and amino-acids.  For example, lipid peroxidation results in formation of 
oxidized lipid compounds such as 4-hydroxynonenal.  In this study, the marker of lipid oxidative 
modification, 4-HNE, was selected because of the good performance of antibodies directed 
towards these epitopes.   
 
In people, the pancreas is considered one of the least well-endowed organs in regards to overall 
antioxidant status (Robertson et al., 2004).  The results of our current study suggest that the beta 
cells may be particularly sensitive to oxidative modification since extensive oxidative 
modification was found in many of the normal cats.  Oxidative stress is one proposed mechanism 
of beta cell dysfunction and has been indicated as a trigger of apoptosis(Donath et al., 2005).  
Generation of ROS and imbalance of the REDOX potential of the cell is also implicated as a 
potential second messenger system for the beta cell.  The beta cell’s metabolic rate is dependent 
on the influx of glucose from the surrounding environment via the constitutively active GLUT-2 
transporter.  Excessive energy available to the cell will result in additional ROS generation by the 
mitochondria via oxidative phosphorylation.  The increase in ROS has been associated with 
changes in gene expression, in particular up regulation of uncoupling protein-2 which is believed 
to be protective to the beta cell by uncoupling oxidative phosphorylation and reducing oxygen 
radical generation.  The finding of oxidative modification in beta cells of the control cats and in 
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the kitten suggests that oxidative modification may be a characteristic of the normal beta cell.  
Furthermore, the increases in oxidative modification and oxidative stress seen in hyperglycemic 
and obese cats may indicate that these are early events in the pathogenesis of beta cell 
dysfunction in the cat. 
 
IAPP is a 37-residue polypeptide hormone produced by the pancreatic beta cell and co-processed, 
packaged, and released with insulin in response to increased serum glucose concentrations.  Like 
humans and non-human primates, feline IAPP is capable of misfolding and producing large, 
extracellular conglomerations of fibrillar amyloid in the tissues surrounding the pancreatic islet.  
The precise mechanisms of IAPP mis-folding are incompletely understood, although the peptide 
sequence from amino acid positions 25-29 appears to be critical for the production of amyloid.  In 
cats and people, this sequence allows folding of the peptide into beta-pleated sheets under 
appropriate conditions.  Native murine IAPP is unable to spontaneously fold and it is believed to 
be due to substitution of multiple proline residues within positions 25-29 of the peptide 
(Westermark et al., 1990).  Inappropriate peptide processing as well as vesicular pH, zinc 
concentration, and molar concentration ratio of IAPP to insulin have all been proposed as 
possible mechanisms promoting misfolding of IAPP into multimeric amyloid (Brender et al., 
2010; Jaikaran and Clark, 2001).   
 
Once produced, lower-order multimers of amyloid (tetramers, decamers, etc) are suspected to be 
directly toxic to cells largely via disruption of cell membrane integrity (Meier et al., 2006; Weise 
et al., 2010; Zhao et al., 2009).  As the misfolded proteins continue to accumulate, they fold into 
larger, fibrillar amyloid which is deposited into the surrounding tissues.  It is this fibrillar amyloid 
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that is visible with standard histopathology as amorphous material effacing normal islet 
architecture.   
 
In our study, amyloid deposits were found in 8/9 diabetic cats and in 1/10 control cats.  These 
findings are consistent with previous reports that suggest amyloid deposition is common in, but 
not a pre-requisite for development of T2D in the cat (Ma et al., 1998).  These findings are 
inconsistent with reports describing 83 random-sourced cats in Queensland, Australia, in which 
greater than 90% of apparently healthy, random-sourced cats had amyloid deposits within their 
pancreas (Lutz et al., 1994b). It is impossible to draw conclusions about the population based on 
this small sample set, but one could postulate that differences in amounts of amyloid found in the 
pancreas of normal cats may be heavily influenced by regional population genetics and diet.  
 
Local paracrine and autocrine inflammation is also considered a key component in the loss of 
beta cell mass.  In this study, we confirmed the accumulation of pro-inflammatory cytokines IL-
1β and IL-6 in the pancreatic islet, presumably within the beta cell.  Increased staining for IL-1β 
in obese, hyperglycemic cats suggests that pro-inflammatory cytokine signaling may be involved 
in the mechanism of pancreatic beta cell dysfunction.   The possible importance of IL-1β 
signaling in beta cell pathogenesis is supported by studies in people using a novel IL-1 β receptor 
antagonist that have shown a return to normoglycemia in diabetic patients taking the drug (Larsen 
et al., 2009). 
 
Positive staining for insulin was found in all samples including the diabetic animals.  Type 2 
diabetic cats experience a combined peripheral insulin resistance as well as gradual decline in 
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pancreatic insulin production capacity, so it is not surprising that there is a very small residual 
insulin producing capacity in even long-standing diabetic cats.  The vast majority of the insulin 
staining in the pancreas of the diabetic cats was not within an identifiable islet structure.  Instead 
these individual or small clusters of cells were seen scattered in the parenchyma.  These 
“orphaned” beta cells may have been derived from islet-associated beta cell replication or may be 
the result of beta cell neogenesis from pancreatic ductal epithelium (Hui et al., 2001; Xu et al., 
2008).   
 
The samples selected for the normal control group originated from a group of shelter cats being 
euthanized during routine population control.  Although each individual was identified as 
apparently healthy, it was not possible to complete a comprehensive physical examination or 
biochemical analysis to rule out systemic illnesses.  As such, it is possible that cats in the normal 
group may have had some degree of subclinical illness that was undetected.  Precise 
measurements of age were not possible as each control cat was identified as a “stray.”  Based on 
dental examination and overall body size and condition, it was estimated that all cats were young 
adults, probably less than five years of age.  It is possible that one or more of the cats may have 
been older than they appeared.   
 
Age and recent medical history were known for each of the cats in the diabetic group.  Six cats in 
the diabetic group died as a direct result of complications from diabetes.  One cat died of 
respiratory failure due to pulmonary neoplasia, another cat died of congestive heart failure, and a 
third died of mast cell neoplasia.  The presence of comorbidities could theoretically impact the 
finding of oxidative modification or inflammation.  Two of the diabetic cats were newly 
diagnosed and died shortly after diagnosis as the result of complications of their disease (diabetic 
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ketoacidosis for one and hyperglycemic-hyperosmolar syndrome in the other).  Another of the 
diabetic cats had only periodically required insulin therapy over the year prior to death.  At the 
time of death the patient was receiving parenteral insulin therapy.  The variability in this 
population may explain some of the variability in our findings.  A similar study in a larger group 
of cats may help better describe if certain pathologic changes are more specific to a particular 
subset of cats.   
 
The pancreata studied from diabetic cats likely represents an “end stage” of disease.  Pancreatic 
islets were typically missing, heavily vacuolated, or completely effaced by amyloid in the 
diabetic cats. There was profound loss of beta cell mass and so identifying the role of oxidative 
modification or inflammation during the course of disease progression was impossible.  Study of 
a large number of clinically normal cats who are at high risk of T2D such as morbidly obese cats 
may provide an opportunity to “catch” disease as it progresses and better help describe the 
mechanisms active during the gradual development of T2D in a way that this study cannot.  It 
was for this reason that the group of study cats was used as a comparison.  The hope was that the 
better-known and strictly controlled health status of the study cats would help eliminate some of 
the variability inherent to cats sourced from the shelter.  Despite the differences in their history, 
both groups of cats had clear presence of oxidative modification and inflammatory cytokines 
within the islets.  Even more interesting was the finding that the study cat group saw an overall 
increase in these markers in the islet after they were obese and hyperglycemic for several months.   
 
Immunohistochemistry is, at best, semi-quantitative and this is a major disadvantage of this study.  
It is impossible to measure actual quantity of protein or evaluate function.  Detection by antibody 
of IL-1, IL- 6, IAPP, and insulin does not allow any definitive statements regarding biological 
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functionality of these hormones and cytokines.  The antibodies used could detect immature 
hormone or cytokine and therefore cannot discriminate between active or inactive peptides.  In 
this study, IHC was used because it provided a very useful semi-quantitative technique for 
retrospective study where protein quantification, function, or gene expression experiments were 
impossible to perform.  Additionally, IHC allows localization of staining and morphometric 
identification of islets versus exocrine tissues. 
 
In the current study, we have shown that oxidative modification, inflammatory cytokine 
signaling, and misfolded proteins accumulate in the beta cells of both normal and diabetic cats.    
These findings, together with our findings from a subset of apparently healthy study cats, suggest 
that inflammation and oxidative modification are present in normal cats and that their expression 
increases very early on during the development of disease.  Future studies focusing on these 
earlier time-points are needed to understand the factors that function in protection of the islet beta 
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Figure 2.1. Representative section from a control cat (A) and diabetic cat (B).  The control islet 
has normal morphology with a typical islet structure indicated by the large arrows.  The endocrine 
islet is surrounded by the exocrine acini (small arrows).  In the diabetic cat the islet has been 





Figure 2.2. Insulin staining of pancreas from a control cat (A) shows the insulin positive cells to 
be largely around the periphery of the islet.  In the diabetic cat (B), individual and clusters of 
insulin positive cells are seen within the adjacent parenchyma (small arrow) and only a few 
insulin positive cells remain within an islet that is effaced by amyloid (large arrow).  Fig. 2C 
compares the mean insulin positive area per total pancreas area between control and diabetic cats 





Figure 2.3. IAPP staining of the pancreas from a control cat (A) shows the IAPP positive cells to 
be largely around the periphery in a pattern identical to that seen with insulin (arrow).  In the 
diabetic cat (B), however, the deposits of amyloid stain less intensely for IAPP (arrow) while a 







Figure 2.4.  Thioflavin-S stained sections of a pancreas were used to identify deposits of amyloid.  
A typical image of a pancreas from a control cat with no amyloid (A) in comparison to a pancreas 







Figure 2.5. Staining for IL-1β varied greatly between groups.  In control cats (A) the staining is 
around the periphery and consistent with beta cells (arrow).  In diabetic cats (B) there is rare IL-
1β staining in islet remnants.  In the additional control cats, there is a clear difference in the 
staining intensity from baseline biopsy (C) and post biopsy taken after sustained obesity and 
hyperglycemia (D).  Islets of a four month old kitten also show positive IL-1β staining in islets, 
although with less intensity as was found in control cats (E).  Fig. 5F compares mean area 
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staining positive per total islet area between control and diabetic cats (p<0.01).  Fig. 5G compares 
mean area staining positive IL-1β per total islet area between samples taken at baseline and post 
treatment in the additional control group (p=0.004). To support the presence of inflammatory 
cytokines in the control islets, a subset of sections from control cats were stained for IL-6 (H).  
Cells around the periphery of the islet stain positive for IL-6 in a similar pattern to that seen for 





Figure 2.6. Oxidative modification was identified in nearly all islets from normal cats (A) and is 
highlighted by the arrows.  In diabetic cats there was a more varied appearance of oxidative 
modification.  In some islet remnants with amyloid there was no positive staining (B), while in 
others there was extensive staining for 4-HNE (C).  In the additional control cats, there is a clear 
difference in the degree and intensity of staining found in the samples from baseline (D) and after 
sustained obesity and hyperglycemia (E).  Fig. 6F compares mean area staining 4-HNE positive 
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per total islet area between samples taken at baseline and post treatment in the additional control 
group (p=0.006).  Evidence of oxidative modification was also seen in a young kitten (G), 








ISOLATION AND CULTURE OF FELINE PANCREATIC ISLETS 
 
3.1 Introduction 
Efforts to better understand the mechanisms underlying beta cell dysfunction 
accompanying the development of feline diabetes mellitus have been complicated by a lack of 
species-specific cell lines and tissue culture protocols.  Although insulin synthesis, demand, and 
sensitivity of peripheral tissues are influenced by a number of neurohormonal factors, the beta 
cells within the pancreatic islets of Langerhans are solely responsible for the production of insulin 
and beta cell loss of function is a prerequisite to development of clinical disease.  Therefore, the 
ability to study isolated pancreatic islet cells in vitro is important in unraveling the 
pathophysiology of feline diabetes.   
Islets of Langerhans are small, discreet islands of endocrine cells distributed throughout 
the pancreas.  Islets are composed of five primary cell types, each with different primary 
secretory products: alpha cells produce glucagon, beta cells produce insulin and islet amyloid 
polypeptide, delta cells produce somatostatin, epsilon cells produce ghrelin, and PP cells produce 
pancreatic polypeptide.  There is considerable paracrine interaction between the cells of the 
pancreatic islet, most notably between alpha and beta cells. Because of the relative complexity of 
the islet microenvironment and the likelihood for paracrine interaction among component cell 
types, it is valuable to study beta cells while still maintaining islet integrity.
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Isolated pancreatic islets from people, rodents, and pigs are commonly used in research 
and procedures for isolation and culture of these islets are well described in the literature.1-6 Most 
procedures require a collagenase digestion of the organ and either density centrifugation or 
manual selection of individual islets to separate islet material away from exocrine tissue.  Yields 
in the hundreds or thousands of islets per pancreas are possible in some species.7,8 Attempts to 
isolate pancreatic islets from cats have been less successful than those described in other species, 
with poor yields of islets clean of exocrine tissue. 
The purpose of this study was to describe a technique for the isolation and culture of 
feline pancreatic islets.  We hypothesize that feline pancreatic islets can be isolated and 
maintained in culture without loss of function for a period of two days and with good viability for 
a period of five days.   
3.2 Materials and methods 
Fresh pancreases were collected from random-source cats euthanized at a local animal 
shelter as part of a routine population control program.  Cats of any age greater than six months 
were included.  The cats were identified as apparently healthy at the time of euthanasia by shelter 
personnel.  Individuals diagnosed as pregnant or lactating and those with severe systemic disease 
or injury (e.g. excessively thin, life-threatening injury, severe gastrointestinal or respiratory 
illness) were excluded.  Euthanasia was performed by shelter staff using a pre-medication of 
xylazine (AnaSed, 16.6mg xylazine/cat, Lloyd Labs, Shenandoah, IA, USA) and ketamine 
(Ketalar, 83mg ketamine/cat, Henry Schein® Animal Health, Dublin, OH, USA) followed by 
intravenous overdose of barbiturate medication (Fatal-Plus, 1170mg pentobarbital/cat; Vortech 
Pharmaceutical, Ltd, Deerborn, MI, USA).  Islet isolation and stimulation was completed in 10 
cats including one neutered male, four intact males, two spayed females and three intact females.  




3.2.1 Organ removal 
Pancreases were collected from cadaveric cats immediately after euthanasia. The cranial 
mesenteric vein was isolated and catheterized with a 24 gauge polypropylene intravenous 
catheter.  Forty to sixty milliliters of ice-cold organ storage solution (Belzer UW® Cold Storage 
Solution, Bridge to Life, Columbia, SC, USA) was slowly infused.  The pancreas was then gently 
removed using a combination of blunt and sharp dissection.  The pancreas was transported while 
bathed in cold storage solution on ice.  Cold ischemic time elapsed from organ collection to 
initiation of collagenase digestion was between 90 and 240 minutes. 
3.2.2 Isolation of purified islets and initial culture 
Dithizone solution was prepared by mixing 33mg dithizone (Sigma-Aldrich, St. Louis, 
MO, USA) in one milliliter absolute ethanol (Sigma-Aldrich, St. Louis, MO, USA) followed by 
alkalization using three drops 10N sodium hydroxide (Sigma-Aldrich, St. Louis, MO, USA).  
After thoroughly vortexing, the solution was added to 300ml PBS and pH was slowly adjusted to 
a final pH of 7.4 using hydrochloric acid (Sigma-Aldrich, St. Louis, MO, USA).   
Collagenase solution (Liberase TL Research Grade, Roche Life Science, Indianapolis, 
IN, USA) was prepared in 48ml warmed (37°C) Hanks’ Balanced Salt Solution (HBSS; Sigma-
Aldrich, St. Louis, MO, USA) to a concentration of 1.081 Wünsch units/ml.  The prepared 
collagenase was injected into the pancreas via trans-capsular injection in multiple sites.  
Approximately 30ml prepared solution was required to inflate the pancreas.  The pancreas was 
then incubated with the remaining solution in a 37°C orbital shaker water bath at 300rpm.  The 
pancreas was first inspected after 20min and digestion was continued until the pancreas visually 
appeared adequately digested (typically 25min). 
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The entire digested pancreas was passed through a 0.5mm wire mesh strainer and rinsed 
with four volumes ice-cold HBSS with 10% fetal calf serum (Gibco, LifeTechnologies, Grand 
Island, NY, USA).  The filtered material was allowed to rest 5min on ice and then all visible 
material accumulated on the bottom was transferred to a pair of 50ml conical vials and 
centrifuged at 300xg for 5min.  The supernatant was discarded while leaving the lower 5ml 
untouched (to avoid disturbing the cell pellet) and the pellet was re-suspended in 40ml ice-cold 
HBSS with 10% FCS and centrifuged again.     
The upper one half of the washed pellet was suspended in 15ml prepared dithizone and 
15ml room temperature HBSS with 10% FCS and incubated for 10min.  Individual islets free of 
exocrine pancreatic tissue were then handpicked using an inverted microscope and a 
micropipetter.  Groups of 50 islets were embedded in 75µl extracellular matrix material 
(Matrigel®, Corning®, Tewksbury, MA, USA) and plated into 24-well tissue culture treated 
polystyrene cell culture plates (Costar®, Corning®, Tweksbury, MA, USA).  Islets were allowed 
to recover 24h in media consisting of CMRL-1066 (Gibco, LifeTechnologies, Grand Island, NY, 
USA) containing 34ng/ml IGF-2 (R&D Systems, Minneapolis, MN, USA), 6.25ng/ml selenium 
(Sigma-Aldrich, St. Louis, MO, USA), 6.2µg/ml transferrin (Sigma-Aldrich, St. Louis, MO, 
USA), 100units/ml penicillin (Gibco, LifeTechnologies, Grand Island, NY, USA), 100µg/ml 
streptomycin (Gibco, LifeTechnologies, Grand Island, NY, USA), and 10% fetal calf serum 
(Gibco, LifeTechnologies, Grand Island, NY, USA).  For functional assays, media was 
exchanged after the first 24h for stimulation media.  For viability studies, media was changed at 
24h and then every 48h with either a serum-containing or serum-free CMRL-1066 media as 
described above. 
3.2.3 Islet viability and functionality 
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Viability of islets was assessed using qualitative examination of intact islets after staining 
with a commercially available calcein am/ethidium bromide assay (LIVE/DEAD®, Life 
Technologies, Grand Island, NY, USA).  LIVE/DEAD® viability was assessed at five days post 
isolation in islets grown in both serum-containing and serum-free media.   
Release of lactate dehydrogenase (LDH) into the media as the result of cell death was 
also used as a measure of islet viability.  Media was changed after a 24h recovery period and 
replaced with serum-free CMRL-1066.  Media was changed on day three and five and the 
proportion of total LDH measured in the media was compared to that remaining in the cell pellet 
using a commercially available LDH assay (Cytotox 96 ® Non-Radioactive Cytotoxicity Assay, 
Promega, Madison, WI, USA).  Percent viability was expressed as [LDHcell pellet/ (LDHcell pellet + 
LDHmedia)] * 100. 
Islet functionality was evaluated 24h after isolation using glucose stimulated insulin 
production and release.  After recovery media was removed, the cells were incubated 15min in 
freshly prepared Krebs-Ringer Bicarbonate Buffer (115mM NaCl, 4.7mM KCl, 1.28mM CaCl, 
1.2mM KH2PO4, 1.2mM MgSO4, 1.0µMol HEPE, 24mMol NaHCO3, pH 7.4) with 1.4mMol 
glucose.  Following this wash step, islets were incubated 120min in KRBB 1.4mMol glucose 
(pre-stimulation).  After two hours, the media was exchanged and islets were incubated in either 
KRBB with 20mMol glucose (stimulation buffer) for 24 hours or fresh KRBB with 1.4mMol 
glucose (basal buffer) for 24 hours.  Insulin content of the media and of the cell pellet was 
determined using a commercially available feline insulin ELISA (Mercodia, Uppsala, Sweden) 
and was normalized to the total protein content of the pellet (µg/ml).  Insulin release into the 
media after stimulation was available for eight of the cats whereas insulin content of the cell 
pellet was available for all ten cats. 
3.2.4 Statistical Analysis 
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All non-parametric data was normalized by natural log transformation.  For islet 
stimulation assays, a two-tailed, paired, student’s t-test was used to test for significance between 
the mean stimulated and resting insulin content of the cell pellet.  Differences between groups 
were evaluated using a software program (SigmaPlot, Systat Software Inc, San Jose, CA, USA).  
Differences were considered significant when the calculated p-value was <0.05. 
3.3 Results 
3.3.1 Islet yield and purity 
A typical pancreas yielded 150 islets completely free of exocrine tissue, although actual 
numbers varied between 125 and 300.  (Figure 3.1a)   
3.3.2 Islet viability 
Islet viability after five days maintained in serum-containing media was estimated to be 
greater than 90% based on visualization of intact islets stained with LIVE/DEAD®.  (Figure 3.2a-
b)  In contrast, islets cultured in serum-free media had larger numbers of ethidium staining nuclei 
within the islets, indicating more cell death. (Figure 3.2c-d)  Islets that survived the first 24 hours 
after recovery tended to remain intact and morphologically unchanged over the five days of 
culture.  When viability of islets cultured five days in serum-free media was estimated based on 
release of LDH, islet total cell viability was calculated to be 77%. 
3.3.3 Glucose stimulated insulin release 
Glucose stimulated insulin release into the media was completed for eight cats (n=3 intact 
males, n=5 intact female) and a wide range of responses were produced.  Some cats showed a 
robust response and others showed no effect (or a negative effect) of glucose stimulation.  The 
difference of magnitude change in media between stimulated and unstimulated controls was not 
significant. (p=0.67, Figure 3.3)  To investigate whether the lack of consistent responses could be 
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related to a failure of insulin trafficking and release from the beta cell rather than failure of 
transcription/translation, total islet insulin content in both stimulated and unstimulated islets from 
the same individual were compared.  There was a trend towards higher insulin in the stimulated 
islets when data from all 10 cats were included in analysis. (p=0.06, Figure 3.4a)   When males 
and females were evaluated separately, males showed increased insulin in the stimulated islets as 
compared to unstimulated controls, although the difference was not significant. (p=0.1, Figure 
3.4b)  In contrast, only 1 of 5 female cats showed any evidence of response to glucose challenge 
with the other four cats containing mildly decreased insulin in stimulated islets compared to 
controls. (p=0.3, Figure 3.4c)  When the magnitude change in insulin content of stimulated vs 
control islets from males or females was compared, there was a trend for islets from males to 
have greater relative stimulation than those from females. (p=0.06, Figure 3.4d)  
No clear patterns were identified when results of both the insulin release and islet insulin 
content from the same individual were compared. There was evidence of both glucose stimulated 
insulin release and increase in pellet insulin content for only one of the nine cats.  In three cats, 
glucose stimulation resulted in a decrease of insulin released into the media and in the cell pellet.  
In all other cats there was no parallelism between the results of insulin release and pellet insulin 
content. (r2=0.04, p=0.65, Figure 3.4e)  
3.4 Discussion 
3.4.1 Islet Isolation  
Yields of purified islets vary between species.  An average mouse pancreas is expected to 
yield approximately 300 islets, which is believed to be between 10-30% of the total islet 
volume.3,9 Slightly better yields are common from human pancreases.  The total number of islets 
per adult human pancreas is estimated to be greater than 1 x 106, and yields of 250-450,000 islets 
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(25-40%) are common.10-12 Similar numbers of isolated islets are seen in adult pigs where yields 
of greater than 250,000 islet clusters are typical.5   
In contrast, attempts to develop techniques for the isolation of large numbers of highly 
pure islets from the cat have been less successful.  Of the two published protocols for islet 
isolation in the cat, neither protocol produced a total number of purified islets similar to the 
number of purified islets described routinely in other species.13,14 Maeno, et al reported isolating 
less than 300 islets free of any exocrine tissue but a mean of 2200 “islet like clusters”.  Zini, et al 
did not quantify the number of purified islets but estimated them to represent less than 2% of the 
total number of islets.  There are no reports quantifying the total number of islets in the feline 
pancreas, but the total islet mass is reported to be 3% of the pancreas.15 Both of these 
investigations used the same collagenase product and a similar digestion procedure.  The reasons 
for this disparity between cats and other species are not understood, but may involve 
ultrastructural anatomy of the peri-islet space, enzyme selection and delivery, connective tissue 
composition, or native mechanisms intended to protect the pancreas against autodigestion.   
Ultrastructural investigation of the interstitial space surrounding the pancreatic islet in the 
cat reveal a fairly thin layer of connective tissue surrounding the islet in contrast to that described 
in people or rodents.13,16 The authors of one study hypothesized that the lack of connective tissue 
makes it less likely that collagenase digestion of the organ can liberate large numbers of islets.13 It 
is also possible that it is the collagen composition of the connective tissue fibers and not 
anatomical thickness that is influencing the inconsistent effect of the selected collagenase 
preparation in cats as compared to other species.  One study described remarkable variability in 
the type and amount of collagen and laminin as well as the organization of connective tissue and 
cell adhesion molecules from the peri-islet space of dogs, people, rats, and pigs.16 The 
composition of peri-islet matrix in cats has not been studied. 
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The yield of highly purified islets in this study is higher than what was reported 
previously in cats.  In those reports, the major product of digestion were “islet-like clusters” 
which are clusters of cells that predominantly include islets with varying degrees of exocrine 
tissue associated with the islet.   
Infusion of the pancreas with collagenase solution is often accomplished via cannulation 
of the pancreatic duct or the common bile duct in species other than the cat.  The cat presents an 
anatomical challenge due to the small size of the pancreatic duct and the presence of an accessory 
pancreatic duct in some individuals that makes it difficult to adequately inflate the organ without 
careful surgical dissection.  Because of the anatomical difficulties and the lack of adequate, clean 
surgical space in the shelter euthanasia facility, trans-capsular injection of collagenase solution 
after cold-storage transportation of the intact organ from the shelter to the laboratory was 
selected, similar to the technique used in previous studies.  Trans-capsular injection of 
collagenase solution was effective at inflating the entire pancreas and appeared to provide 
consistent, homogenous digestion of the organ with little to no macroscopically un-digested tissue 
remaining.  However, in at least one study investigating collagenase digestion of the human 
pancreas, it was demonstrated that collagenase infusion via the pancreatic duct was more 
effective at reaching the surface of the islets as compared to collagenase insufflation via trans-
capsular injection.12 If this is also the case in the feline pancreas, efficiency of digestion may be 
improved by infusion of enzyme through the pancreatic duct.   
Islet microvasculature is unique as compared to the vasculature of the exocrine pancreas.  
Islets are heavily vascularized by fenestrated capillary beds to allow rapid diffusion of peptide 
hormones (insulin and IAPP) into circulation.  Of particular interest is that islet vascular 
endothelium expresses alpha-1 proteinase inhibitor and islet endothelium appears to be resistant 
to the digestive effects of trypsin.17 This mechanism, which is intended to be protective of the 
islets because of their proximity to the aggressive digestive enzymes contained in the exocrine 
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pancreas, may help explain some of the variability in islet yield.  In fact, a common finding in our 
isolation procedures in cats is that many islets remain attached to exocrine tissue via one or more 
capillaries, and capillary remnants are commonly seen projecting from the islet surface after 
isolation. (Figure 3.5) 
Islets were handpicked for purity in this study.  Islet morphology varies tremendously 
within the same individual.  Islets range in size from as little as 50µm to as large as several 
hundred micrometers in diameter.  Moreover, unstained islet color is very similar to the unstained 
acinar tissue surrounding the islets.  Because of this, it is extremely difficult to reliably identify 
islets based solely on morphology.  Beta cells are rich in zinc and so the use of dithizone, a zinc 
chelating dye, provides a reversible way to positively and specifically identify islets in pancreas 
digestate. 
3.4.2 Islet Viability 
Islet viability was determined using two different assays.  The LIVE/DEAD® assay is 
particularly useful as a non-lethal method for identifying cells with intact intracellular metabolic 
pathways (calcein am) as compared to non-viable cells with damaged cell membranes (ethidium).  
A combination of the three dimensional nature of the islet and the dramatically different intensity 
of fluorescence of each compound made accurate quantitative measurements using the 
fluorescent assay difficult.  Therefore, subjective measurements of islet viability were made based 
on still images of several focal planes within the same islet.  Using this method, viability of intact 
islets was estimated to be greater than 90% at 24hrs. 
Release of LDH into the media was employed as an objective measurement of cell death 
in the system.  The LDH assay was heavily affected by the presence of serum in the media.  In 
order to measure total LDH release into the media over the five-day period, groups of islets were 
maintained in serum-free media for LDH assay only.   Because of the concern that maintaining in 
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serum-free media would have a negative impact on cell viability during this time, islets were also 
stained with LIVE/DEAD® and compared to islets maintained in a serum-containing media.  The 
overall viability of islet cells was estimated by LDH release to be 77% after five days in culture 
with serum-free media.  Islets maintained in serum-free media did appear to have greater numbers 
of dead cells as compared to those grown in serum containing media. (Figure 3.2c-d)  Therefore, 
it is likely that actual viability of islets when maintained in CMRL media containing 10% fetal 
calf serum (the media of choice) is higher than that which was calculated using the LDH assay. 
Viability calculated in these experiments was of the entire islet.  It is impossible to know 
if one cell type was less viable than others.  It is well documented that freshly isolated islets 
undergo a change in cellular composition as a result of the isolation procedure.  In particular, loss 
of alpha and beta cells as the result of the collagenase process and cold-ischemic time.18 
Additional experiments are required to determine which cell lines suffer the greatest losses during 
culture in the cat.  Any change in the proportions of different cell types within the islet may alter 
paracrine interactions of islet components and ultimately alter islet function.19 
3.4.3 Glucose Stimulated Insulin Production and Release 
Glucose stimulated insulin release (GSIR) is routinely used as an indicator of retained 
islet function in freshly isolated islets from people and rodents.3,20 Under normal physiologic 
conditions, insulin release in response to increased blood glucose occurs in two phases: an 
immediate phase in which secretory granules ready to dock release their stored insulin cargo 
within minutes of stimulation of the beta cell, and a sustained release phase that can continue for 
minutes to hours.  In islets cultured from rodents, an increase in insulin release of at least two-
fold over one to two hours is expected after glucose challenge.3 The GSIR of freshly isolated 
feline islets in our experiments was inconsistent, with the majority of islets failing to demonstrate 
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a clear physiologic response upon exposure to glucose.  Using a two-fold increase as a cut-off 
value at 24 hours, only two of eight cats showed an appropriate response.   
These results suggest that our freshly isolated feline islets fail to retain their physiologic 
function at 24 hours post isolation.  The reason for this failure of isolation could be the result of 
any one or a combination of the following: sub-optimal culture conditions (media, islet plating 
density, culture vessel) for feline pancreatic islets, excessive damage to islet structure during 
collagenase digestion, exposure of islets to toxic conditions (e.g. hypoxia, oxidative damage) that 
leave the beta cells unable to respond to glucose, inappropriate GSIR protocol for the given 
species, or alterations in islet paracrine signaling resulting from changes in islet cell composition.   
Culture conditions recommended for human and rodent islets differ.  For instance, the 
most commonly used media for rodent islets (RPMI) contains more glucose (10mM) as compared 
to the preferred media for human islets (CMRL-1066 containing 5mM glucose).21 Additionally, 
the ideal supplementation of antioxidants and growth factors for pancreatic islets is not clear.  
Selenium supplementation has been recommended an essential element for several antioxidant 
enzymes.  Transferrin supplementation in media can improve viability of some cell types by 
regulating iron delivery to the cells.  Insulin-like growth factor is important for anti-apoptotic 
survival signaling.21 There are no studies comparing media types or supplements for the culture of 
feline islets. 
Pancreatic islets from several species have been successfully maintained in a variety of 
culture systems.  Some encourage maintenance of extracellular interactions by embedding islets 
in matrix (collagen, elastin, gelatin, fibrin, or complex matrices such as Matrigel®) or by allowing 
single surface contact with a collagen coated or tissue culture treated surface.21-26 Other 
applications call for maintaining the islets in a continuously rotating chamber where the islets are 
grown without extracellular anchoring and are free-floating in media.27   
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A wide range of different culture conditions were investigated in attempts to find 
conditions that provided the most ideal support for feline islets.  The glucose stimulated insulin 
release of islets under each of these conditions was similarly inconsistent.  The selected 
combination of CMRL-1066 with serum, antioxidants, and growth factors used in this experiment 
was based on review of the relevant literature relating to culture of human pancreatic islets.21 Our 
preference for human islet culture conditions was based on the concept that humans and cats, but 
not rodents, share similar clinical and islet histopathologic pancreatic findings (beta cell 
sensitivity to glucose, inflammatory cytokine signaling, and islet amyloidosis) during 
development of disease.    
The goal of a collagenase digestion is to be gentle enough to maintain healthy islets, but 
aggressive enough to achieve dispersion of the tissue components.  Although islets remained 
intact and grossly normal under light microscopy, ultrastructural evaluation using electron 
microscopy of freshly isolated rat islets suggests the presence of major damage to the cells around 
the periphery of the islet and to the islet basement membrane.28 The damage is sufficient to cause 
death of many of these cells.  Freshly isolated rat islets were markedly deficient in alpha, delta, 
and PP cells which are found in the periphery of a rat islet.28 The anatomical arrangement of the 
feline islet is different than that of humans and rodents.  In the cat, beta cells are found largely 
around the periphery and alpha cells more frequently in the central region of the islet.  This is in 
contrast to rodents in which the beta cells form the core of the islet with a higher proportion of 
alpha cells along the periphery of the islet, and people with alpha cells scattered throughout the 
islet but forming a mantle around the islet as well.18,29 Identification of a change in distribution or 
location of different cell types before and after isolation of feline islets was not attempted in the 
current study.  A preferential loss of beta cells is anticipated, given the peripheral nature of these 
cells in the islets.  However the susceptibility to the stresses of isolation of the other islet cell 
types is unknown. 
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Another potential explanation for the lack of reliable GSIR is a toxic insult to the beta 
cells during the isolation process.  All enzyme, media, and buffer solutions used were certified 
endotoxin free and were prepared new for each pancreas. The entire process of isolation includes 
exposure to a variety of temperatures and pH.  The pancreas is chilled as quickly as possible after 
euthanasia of the animal and maintained on ice until ready for digestion.  Cold ischemia times of 
24 hours have been shown to have minimal effects on islet function in people and the cold 
ischemia of the feline islets was limited to less than 4 hours.7,30 Nevertheless, increasing 
temperature for the collagenase digestion and then immediately chilling the digested tissue on ice 
likely induces substantial cell stress.  Handpicking of islets requires between one and two hours 
per pancreas.  Media is held at room temperature under room air during the hand-selection 
process and as such, the pH of the media is slightly higher than it would be if maintained under 
controlled conditions with 5% carbon dioxide.  The variation in temperature, dissolved gasses, 
and pH undoubtedly introduces additional cellular stresses during the isolation period.  Because 
of the expectation of cell trauma and inevitable loss of viability, islets were allowed to recover for 
24 hours prior to starting any experiments.  It is possible GSIR results may be different if testing 
was performed at the time of isolation or after an extended recovery period of several days.   
The GSIR procedure used in this study is modified from traditional GSIR protocols.  As 
described before, insulin release into the media is bi-phasic with an immediate release of insulin 
(within minutes) from granules ready to dock and release contents, followed by a more sustained 
(minutes to hours) plateau of insulin release as long as the stimulus (glucose) is present.  In early 
experiments, little evidence of glucose responsiveness was detected from islets after two hours of 
stimulation.  In order to account for the possibility that a failure of GSIR seen in these early 
experiments was simply due to a sluggish, but not absent, physiologic response we modified the 
protocol by extending stimulation incubation time.   The longer incubation should not have any 
impact on the short-term insulin release but would allow additional time for delayed changes in 
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insulin biogenesis and trafficking to develop.  It is possible that the extended incubation in a 
buffered salt solution and not an essential media had a negative impact on islet function. 
It is well documented in people and rodent islets that the isolation process induces 
alterations in islet cell composition, specifically, the loss of alpha cell population.  Studies in 
human islets have demonstrated that even a slight over-digestion of the islet results in a dramatic 
increase in loss of alpha cells (up to 85%).18 Insulin release is regulated by a number of paracrine 
and endocrine signals in addition to glucose, principle of which is glucagon.  A deficiency of 
glucagon has a negative impact on GSIR.  The importance of glucagon in GSIR in isolated islets 
was demonstrated in a study using freshly isolated, alpha-cell deficient human islets in which 
GSIR was severely blunted without but nearly completely restored by incubation with glucagon.18 
It is possible that a similar phenomenon of altered islet paracrine signaling is responsible for the 
inconsistent GSIR seen in this study.     
Finally, although islets are distributed throughout the pancreas and have the same overall 
composition, there are nevertheless differences between some islet populations.  For instance, 
islets with a higher or lower proportion of alpha cells relative to beta cells may respond 
differently to glucose challenge because of glucagon’s paracrine role in the islet.  It has also been 
well described in human and rodent islets that larger islets tend to have lower insulin content and 
are less responsive to glucose than are smaller islets.31,32 We cannot rule out the possibility that 
the small number of islets isolated could over-represent a particular population of islets that, 
because of their anatomical location in the pancreas or peri-islet connective tissue composition, 
are more likely to separate from the exocrine tissue but will not, because of the islet cell makeup 




The aims of the current study were to develop techniques for the isolation of highly pure 
feline pancreatic islets and to demonstrate viability and functionality of freshly isolated islets.  
Collagenase-based digestion of cadaveric donor pancreases yielded sufficient highly pure islet 
tissue for many in vitro applications.  Viability of cultured islets was good over a five day culture 
period and improved in serum-containing basal media.  Function of islets as described by either 
the glucose stimulated insulin release or cell insulin content appears to vary greatly between 
individuals and these two measurements of function can be inconsistent within the same 
individual.   
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Figure 3.1.  Typical semi-pure collection of islets.  Free, dithizone islets (wide black arrow) are 
easily distinguishable from acinar tissue (thin black arrows) based on color and morphology.  




Figure 3.2.  Representative images of the same islet stained with LIVE/DEAD® reagents.  Green 
cells represent viable cells whereas individually staining red nuclei represent dead cells without 
intact cell membranes.  Figures a-b represent islets cultured 5 days in serum-containing media.  





Figure 3.3. Magnitude change of insulin released into the media in stimulated vs unstimulated 
control islets.  Resting media was replaced with media containing either high (stimulated) or low 




Figure 3.4.  a) Paired samples of stimulated and unstimulated islets.  There is a trend for higher 
insulin content of the cell pellets in stimulated as compared to unstimulated islets after 24hrs 
exposure to high glucose concentrations. (p=0.06)   b) Same as Fig 4a but with data only from 
male cats (n=5) shown.  No significant difference in insulin content of stimulated vs unstimulated 
islets was detected. (p=0.1)  c) Same as Fig 4a but with data only from female cats (n=5) shown.  
No significant difference in insulin content of stimulated vs unstimulated islets was detected. 
(p=0.3)  d) Graphical representation of the fold change in insulin content in stimulated islets from 
the same individual.  Four of ten cats had less insulin in the stimulated cell pellets compared to 
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unstimulated controls.  When the magnitude change in insulin content of stimulated vs control 
islets from males or females are compared, there is a trend for islets from males to have greater 
stimulation than those of females.(p=0.06)  e) Comparison of the magnitude change in insulin 
released into the media vs insulin content of the cell pellet.  Four of nine cats show discordance in 
released insulin content vs insulin content of cells.  There was no correlation between the results 
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EVALUATION OF THE PROTECTIVE EFFECTS OF EXENATIDE ON FELINE ISLETS 
SECONDARY TO ENDOPLASMIC RETICULUM STRESS 
 
4.1 Introduction 
Feline diabetes mellitus (FDM) is the clinical manifestation of insufficient insulin 
necessary to maintain euglycemia.  FDM develops over an extended period of time during which 
a period of increased insulin secretory function serves to overcome peripheral insulin resistance 
to maintain euglycemia.  This compensatory state ultimately fails through a combination of beta 
cell dysfunction and beta cell loss, resulting in clinical signs of unregulated hyperglycemia.  The 
precise mechanisms of beta cell dysfunction and loss are unknown but are thought to include 
oxidative stressors, development of misfolded islet associated polypeptide (IAPP), and 
inflammatory cytokine signaling.  The presence of markers of oxidative stress, inflammation, and 
accumulation of IAPP in the diabetic feline pancreas was demonstrated in data supporting Aim 2. 
The unfolded protein response (UPR) is a mechanism by which cells adapt to 
endoplasmic reticulum (ER) stress as the result of accumulated, misfolded proteins within the 
ER.1 This adaptive mechanism ultimately activates the intrinsic apoptotic pathways if the stress is 
not ameliorated.  Because of the high demand of pancreatic beta cells to produce insulin, 
activation of the UPR is important for maintaining beta cell function.2 In fact, one mechanism by 
which IAPP is believed to induce beta cell toxicity is via excessive stimulation of the UPR.  
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Misfolded IAPP within the beta cells of humans and transgenic rodents is associated with 
increased ER stress and activation of the unfolded protein response (UPR).3,4 
Glucagon-like peptide-1 (GLP-1) is a hormone produced by specialized enteroendocrine 
cells localized in the ileum of cats.  Many down-stream effectors of GLP-1 receptor (GLP-1r) 
binding are described that collectively have a variety of metabolic effects within the beta cell.5 
Potential beneficial effects include enhanced insulin production and release in response to glucose 
stimulation, pro-proliferative signaling, and protection from apoptotic signals principally via 
activation of AKT and PKA pathways.  GLP-1r signaling has been shown to inhibit apoptosis 
secondary to ER stress in cultures of rat beta cells and in murine insulinoma cell lines secondary 
to ER stress.6-9 The availability of isolated feline islets (Chapter 3) has now made it now possible 
to ask a similar mechanistic question in the cat.  
Based on the work in rodents and people, the goal of this study is to investigate the effect 
of the GLP-1 mimetic exenatide on amelioration of ER stress in freshly isolated feline pancreatic 
islets.  We hypothesize that exenatide will reduce activation of apoptosis in pancreatic islets 
exposed to ER stress. 
 
4.2 Materials and Methods 
4.2.1 Islet isolation 
Purified fresh feline pancreatic islets were isolated from 8 cadaveric cats being 
euthanized as part of a routine population control program at a local animal shelter using 
techniques outlined in Chapter 3, with minor modifications.  All cats were young adults and 
included 3 neutered males, 1 spayed female and 4 intact females.  After clipping hair from the 
abdomen, the area was briefly scrubbed and soaked with 70% isopropyl alcohol.  Pancreas organs 
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were infused with a cold-storage solution (CoStorSol, Bridge to Life, Columbia, SC, USA) in 
situ, removed by dissection, and transported on ice.  Collagenase tissue digestion (Collagenase 
NB-8, Serva Electrophoresis GmbH, Heidelberg, Germany) was used to liberate islets from the 
surrounding exocrine pancreatic tissues and islets positively stained with dithizone (Sigma, St. 
Louis, MO, USA) were hand-selected.  Islets from individual animals were divided into five 
groups of roughly 60 islets each and embedded in 90µl extracellular matrix (Matrigel®, Corning®, 
Tewksbury, MA, USA).  Islets were then left to recover 24hrs in basal media (CMRL 1066 – 
Corning Cellgro, Mediatech, Inc, Manassas, VA, USA, with penicillin, streptomycin, l-glutamine, 
and 10% fetal bovine serum – Gibco, LifeTechnologies, Grand Island, NY, USA).   
4.2.2 Induction of ER stress and determination of caspase activity 
After 24hrs recovery time, media was exchanged for fresh CMRL 1066 with antibiotics 
but without fetal bovine serum.  Islets were treated for 24hrs with tunicamycin (TUN) 15µg/ml or 
thapsigargin (TG) 15mMol (Sigma, St. Louis, MO, USA) with or without 10nMol exenatide 
(Byetta®, Amylin Pharmaceuticals, San Diego, CA, USA).  Tunicamycin is a synthetic antibiotic 
that induces ER stress in mammalian cells by blocking N-glycosylation of proteins during post-
translational processing within the ER, resulting in accumulation of misfolded proteins within the 
endoplasmic reticulum and activation of the UPR.  Thapsigargin is a non-competitive inhibitor of 
the sarco/endoplasmic reticulum calcium-ATPase pump (SERCA).  The relative rise in cytosolic 
calcium and depletion of endoplasmic calcium due to dysfunction of the SERCA pump results 
both in induction of the intrinsic apoptotic pathway and inhibits protein processing within the ER 
and golgi apparatus. 
Exenatide treated groups were incubated for one hour with exenatide alone prior to the 
addition of any other compounds to the media.  Stock solutions of tunicamycin and thapsigargin 
were prepared by solubilizing the drugs in 100% DMSO.  The final concentration of DMSO in 
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the treatment media after dilution was 1.5%v/v.  Control islets were maintained in the same 
serum-free media with 1.5%v/v DMSO but without the addition of any drugs. 
Activated caspase 3 was quantified using a luciferase-based luminescent assay 
(CaspaseGlo Caspase 3/7 assay, Promega, Madison, WI, USA).  Luminescence was measured 
(SpectraMax M2, Molecular Devices, Sunnydale, CA, USA) and the results for each group were 
normalized to total double stranded DNA of the cell pellet of that group as measured by 
flurometric assay (Qubit® dsDNA BR Assay Kit, Life Technologies, Grand Island, NY, USA).  
For results to be considered in the final statistical analysis, an increase in caspase activity 
of at least 50% above control had to be present in the TUN or TG only wells.  The intent of 
including these criteria was to limit the effect of experimental variability due to inter-animal 
variation or baseline caspase activation during the collection process thereby allowing the effect 
of exenatide to be discretely examined. 
4.2.3 Statistical Analysis 
Data are presented as mean and standard deviation (mean ± SD).  Data was evaluated 
using a software program (SigmaPlot, Systat Software Inc, San Jose, CA, USA) and differences 
between groups were tested using a two-tailed, paired t-test.  Differences were considered 
significant when the calculated p-value was <0.05. 
4.3 Results 
Exposure of freshly isolated feline islets to both tunicamycin and thapsigargin resulted in 
increased caspase activity to approximately 1.9 times control values.  Tunicamycin increased 
caspase activity 1.88 ± 0.14 (n=5, p=0.005) times control and thapsigargin increased caspase 
activity 1.92 ± 0.15 (n=4, p=0.004) times control.  Treatment with exenatide alone did not change 
caspase activity from that of control (n=4, p=0.1).  Caspase 3 activity was attenuated in islets 
130 
 
treated with exenatide in addition to the ER stress-inducing drug.  In the case of tunicamycin 
treated islets, co-culture with exenatide reduced caspase 3 activity from 3141±1237 in 
tunicamycin treated to 2399±1299 in tunicamycin plus exenatide treated islets. (p=0.01, Figure 
4.1d) Co-culture with exenatide decreased caspase 3 activity from 3141±1237 in thapsigargin 
treated cells to 2399±1299 in thapsigargin plus exenatide treated islets. (p=0.08, Figure 4.1c) In 
three experiments treatment with TUN (or TG) failed to induce an increase in caspase activity.  In 
those samples, the unstimulated caspase activity was nearly twice the mean of controls in all other 
experiments and was outside the 95% confidence interval calculated for control caspase activity 
suggesting a problem occurred in the collection of these islets, such as contamination or excessive 
digestion and loss of cell integrity. 
4.4 Discussion 
The high metabolic rate of the pancreatic beta cell and demands on beta cell ER 
manufacturing capacity leave the beta cell particularly susceptible to stress associated with ER 
dysfunction.  The role of ER stress in beta cell dysfunction has been well described in people and 
rodents, but has not been described in cats.  In this study, ER stress and caspase activation was 
induced in freshly isolated feline islets via two separate mechanisms.  Co-treatment with the 
GLP-1r agonist exenatide resulted in attenuation of caspase activity suggesting that exenatide 
may protect pancreatic islets from apoptosis secondary to ER stress. 
Caspase 3 activity was selected as an outcome variable because overstimulation of the 
UPR secondary to ER stress ultimately result in caspase 3 activation and apoptosis.  Additionally, 
the effect of GLP-1r activation involves multiple pathways, several of which culminate in 
inhibition of caspase 3 activation.  Therefore, caspase 3 activity represented a convergence of 
both GLP-1 signaling and ER stress.  In order to better understand the specific mechanism of the 
protective effects of exenatide, the various components of the UPR and GLP-1 signaling pathway 
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would need to be investigated.  Of particular interest is phosphorylated PERK and eIF2α as these 
have been shown to be central to the effects of GLP-1 activity in human beta cells.  Additionally, 
characterization of changes in the Bcl-2 family of proteins under ER stress and after treatment 
with exenatide would provide insight into activation of the intrinsic pathway of apoptosis.  
(Figure 4.2) 
Three of the eight cats failed to show adequate caspase activation following TUN or TG 
treatment.  All three of these cats also had high baseline caspase activity in the control islets.  
High caspase 3 activity in control islets might be attributed to several potential causes.  Islets 
were allowed a 24 hour recovery period post isolation to recover from the stress of isolation.  
Even with this recovery period, it is likely that there will be some degree of cell stress related to 
the isolation and culture procedures.  The process of isolation involves multiple changes in 
temperature and several hours cold-ischemia time, exposure to collagenase enzyme which can 
disrupt cell integrity, and exposure to agents that may be associated with oxidative stress to the 
cells (as discussed in Chapter 3).  Contamination with a bacterial agent or source of endotoxin 
would result in large increases in caspase 3 activity.  Additionally, donor cats for this experiment 
were sourced from the local shelter and as such they have a varied genetic background, unknown 
age, and unknown health status (beyond appearing healthy to shelter staff prior to euthanasia).   
In order to limit the effects of various growth factors found in fetal calf serum, serum free 
media was used for the 24 hour incubation with tunicamycin and thapsigargin.  The removal of 
protective effects associated with serum (growth factors, albumin, transferrin) may be associated 
with a mild increase in caspase activity.  The effects of serum-free versus serum-containing 
media on caspase 3 activation were not investigated. 
Although not significant, there appeared to be a modest increase in caspase 3 activity in 
islets treated with exenatide alone. Meta-cresol is a preservative used in the formulation of 
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Byetta®.  This compound is commonly used in cosmetics and pharmaceuticals and is well 
studied.  Toxic concentrations of m-cresol vary widely depending on the cell type and response 
investigated (lethality, inhibition of growth, inflammatory cytokine production).  In one study 
evaluating the toxicity of m-cresol on rat isolated hepatocytes, a dose-dependent inhibition of 
mitochondrial respiration was seen at concentrations as low as 0.3nmol/µg protein.10 Based on 
total protein content of similarly isolated and cultured islets used in previous experiments, we 
estimate islets in our experiments were exposed to between 0.3 and 0.5nmol/µg protein of the 
sample.  This would suggest that the dose of m-cresol could produce a negative impact on 
mitochondrial respiration.  In contrast, other studies using cell lines from fish or mice have only 
shown measurable toxicity at concentrations at least 100x the doses to which the islets in our 
experiments were exposed.11,12 
DMSO is also a known toxin to mammalian cells.  Although it is commonly used as a 
cryopreservative in pancreatic islets at a concentration of 10%, it is unclear what concentration of 
DMSO will be toxic under extended culture at 37deg celsius.13,14 Islets from all treatment groups 
in our experiments were exposed to 1.5%v/v DMSO to control for the potential negative effects 
of DMSO at that concentration. 
Finally, the concentration of exenatide used in this experiment was 10nMol, which is a 
greater concentration than what has been described in plasma of cats administered exenatide.  
This dose was extrapolated from the literature in experiments using isolated islets and cell 
cultures in other species.15-18 The pharmacokinetics of exenatide extended release formulation 
(Bydureon®, Amylin Pharmaceuticals, San Diego, CA, USA) in cats have been described.19 A 
mean peak plasma exenatide concentration of 0.27ng/ml (64.5pMol) was achieved after a single 
dose of 0.13mg/kg administered subcutaneously.  This dose resulted in an increase in the area 
under the curve for insulin following glucose stimulation and decreased glucagon concentration 
during hyperglycemic clamp procedure.  The pharmacokinetic profile of the twice-daily exenatide 
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formulation has also been investigated.  In that study, administration of a single subcutaneous 
dose of 1µg/kg exenatide produced a mean peak plasma concentration of 3.0ng/ml (716pMol) 
with similar pharmacodynamic effects.20 Therefore, the dose of exenatide used in the current 
study was roughly 155 times the theoretical in vivo exposure for extended release exenatide and 
14 times that seen with the twice daily formulation. Additional investigations using varying drug 
doses in cultured islets are necessary to evaluate if similar responses are seen to more clinically 
achievable doses. 
4.5 Conclusion 
The purpose of this experiment was to describe the effects of the GLP-1 mimetic 
exenatide on caspase 3 activity in freshly isolated feline islets exposed to ER stress.  Our results 
suggest that exenatide may have a protective effect against caspase 3 activation (and secondarily, 
apoptosis) in islets exposed to severe ER stress secondary to treatment with thapsigargin or 
tunicamycin.  These findings suggest one potential mechanism for beta cell protective effects of 
exenatide on feline islets.   
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Figure 4.1. a. Caspase activity in untreated, tunicamycin treated, and thapsigargin treated 
islets.  b. Caspase activity in data excluded due to failure of tunicamycin or thapsigargin to 
stimulate caspase activity.  Compared to the data in Panel A, the baseline caspase activity in the 
untreated control is significantly (p=0.02) higher suggesting either activation during collection 
and processing or variability due to random source animals.  c. Caspase activity in thapsigargin 
and thapsigargin with exenatide treated groups.  There was no difference between the groups. (n= 
4, p=0.08).  d. Exenatide treatment in addition to tunicamycin was associated with a decrease in 







Figure 4.2.  There are three canonical branches of the UPR.  Accumulation of misfolded or 
unfolded proteins leads to disassociation of GRP78 from UPR mediating proteins, allowing 
dimerization and phosphorylation of IRE1 and PERK and phosphorylation of ATF6.  IRE1 
activation will in turn up-regulate the activity of XBP1s (not shown) which serves as a 
transcription factor to promote chaperone protein production (such as BiP).  Excessive activation 
of IRE1 also activates the JNK pathway leading to apoptosis.  PERK phosphorylates eIF2α which 
up regulates the activity of CHOP.  CHOP functions include induction of mitochondrial stress 
(and activation of the intrinsic pathway to apoptosis) and serving as a transcriptional regulator of 
several pro-inflammatory and pro-apoptotic products.  ATF6 phosphorylation allows for 
translocation of the cytoplasmic domain of the protein to the nucleus where it serves as a 
transcription factor for, among other things, several chaperone and UPR-related proteins.  
136 
 
Thapsigargin inhibits the function of the SERCA pump, thereby depleting ER calcium stores.  
Decreased ER calcium causes ER swelling and promotes misfolding while increasing 
cytoplasmic calcium leads to activation of the intrinsic apoptotic pathway.  Tunicamycin inhibits 
n-glycosylation of proteins, leading to misfolding and accumulation of these proteins within the 
ER.  GLP-1r signaling is anti-apoptotic via several mechanisms: direct inhibition of eIF2α, 
activation of the SERCA pump, inhibition of CHOP, and inhibiting pro-apoptotic Bcl-2 family 
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EVALUATION OF EXENATIDE AS AN ADJUNCTIVE TREATMENT FOR DIABETES 
MELLITUS IN THE CAT 
5.1 Introduction 
The arsenal of treatments available for feline diabetes mellitus is limited and remains 
centered on the eventual requirement of parenteral insulin therapy.  Advances in our 
understanding of the unique glucoregulatory physiology and nutritional requirements of cats as 
well as the addition of new insulin formulations have made for significant improvements in 
treatment outcomes of diabetic cats.  However, these treatments fall short in comprehensively 
addressing the underlying pathophysiology of beta cell dysfunction. 
Feline diabetes mellitus is a clinical disease resulting from insufficient insulin activity to 
maintain normoglycemia.   The reasons for this loss of activity are related both to alterations in 
insulin responsiveness in insulin-sensitive tissues as well as loss of insulin production by the 
pancreatic beta cells in amounts sufficient to match peripheral insulin sensitivity.1 Peripheral 
insulin sensitivity is influenced by factors such as diet, exercise, total body adiposity, and 
endocrinopathies affecting insulin receptor regulation and function (e.g. hypercortisolism, 
hypothyroidism).2,3   
The mechanisms of beta cell loss or dysfunction in the cat are less clear.  Proposed 
mechanisms for loss of functional beta cell mass include direct gluco-lipotoxicity, oxidative 
stress, inflammatory cytokine signaling, and accumulation of misfolded islet associated (or islet 
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amyloid) polypeptide (IAPP).4-8 As with Type 2 diabetes mellitus in people, feline diabetes 
appears to be associated with a gradual loss of beta cell function combined with peripheral insulin 
resistance that appears to occur over an extended period of weeks or even years.  The remaining 
beta cell population attempts to compensate by resisting apoptosis and proliferating under the 
regulation of hormones such as glucagon-like polypeptide-1, insulin, and prolactin.9   
The “incretin effect” refers to the augmented insulin response to enteral nutrients as 
compared to an equivalent parenteral dose.  Incretin hormones are produced by specialized 
endocrine cells within the gut in response to luminal nutrient exposure.  The two most notable 
incretins are glucagon-like polypeptide-1 (GLP-1) and gastric inhibitory peptide (GIP).  These 
incretin hormones have some overlapping physiologic functions including promoting insulin 
production and release in response to glucose, inhibiting apoptosis in beta cells, and inducing 
satiety signals in the brain.10 GLP-1 appears to have more broad-reaching effects on the beta cell 
to include promotion of beta cell proliferation and neogenesis.11-13 Incretin hormones are 
substrates for dipeptidyl peptidase-4 (DPP-4) which is widely expressed in all tissues.  DPP-4 
activity in the intestinal capillary bed and portal circulation rapidly degrade active GLP-1 and 
GIP into inactive peptides and it is estimated that only 25% of hormone reaches portal circulation 
and only 10% reaches the vena cava.14   
Because feline diabetes is the result of a relative inadequacy of beta cell function but not 
necessarily an absolutely loss of beta cell numbers, the therapeutic use of incretin hormones for 
their beta cell insulinotropic, cytoprotective, and cytoproliferative effects is appealing.  There are 
two primary approaches to incretin therapy in the clinical setting.  One is to inhibit DPP-4 
activity, thereby increasing endogenous incretin hormone concentrations.  Another approach is to 
develop incretin “mimetics” that have the same biological activity but are resistant to DPP-4 
degradation.   
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The oral DPP-4 inhibitor sitagliptin (Januvia®, Merck) has been evaluated in a small 
number of cats.15,16 Although one study detected a modest effect on post-prandial insulin 
concentration in healthy cats after administration of sitagliptin, the second study failed to detect 
any effect.                          .   
Exenatide is a synthetic analog of a peptide originally discovered in Heloderma 
suspectum saliva, which shares a 35% sequence homology to GLP-1, has nearly identical 
biological effects but is a poor substrate for DPP-4.  Exenatide is marketed for human diabetic 
patients under the trade name Byetta® as a twice-daily injection and Bydureon® as an extended-
release formulation.  There is an extensive body of literature on the clinical effects of exenatide in 
human Type 2 diabetics, but the body of literature describing the clinical application in veterinary 
patients is still limited.  The pharmacokinetics and pharmacodynamics for both the short acting 
and extended release formulations of exenatide have been studied in healthy cats.16-19 Both 
formulations were associated with an increase in the area under the curve (AUC) for insulin 
following glucose stimulation and showed a similarly high safety margin.   
Based on the documented insulinotropic effect and theoretical cytoprotective and 
cytoproliferative benefits of exenatide in cats, the aim of this clinical trial was to evaluate the 
effect of exenatide as an adjunctive treatment for cats with newly diagnosed diabetes mellitus.  
Our study hypothesis was that the addition of exenatide to standard insulin therapy will be 
associated with better glycemic control as determined by serum fructosamine, decreased insulin 
dose, and reduction in body weight over the 12 week study period. 
5.2 Materials and Methods 
5.2.1 Study Population and Inclusion Criteria  
Cats referred to the Boren Veterinary Medical Teaching Hospital at Oklahoma State 
University with a recent diagnosis of feline diabetes mellitus were enrolled during two separate 
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periods due to a period of unavailability of the insulin formulation used in this study.  Cats were 
enrolled between September, 2008 and June, 2010 and again between July, 2014 and March, 
2015.  A diagnosis of diabetes mellitus was made based on a combination of increased serum 
glucose (greater than 180mg/dL), glucosuria and increased serum fructosamine.   Patients treated 
with exogenous insulin within 30 days prior to admission were excluded.  Cats with concurrent, 
systemic disease not directly related to their diabetes such as hypertension, neoplasia, clinical 
pancreatitis, or endocrinopathies (e.g. hyperthyroidism, hypersomatotropism) were also excluded.  
The study was approved by the Oklahoma State University Institutional Animal Care and Use 
Committee. 
5.2.2 Diagnostic testing 
Upon admission to the study, all cats had comprehensive in-house diagnostics to include 
serum biochemistry panel, complete blood count, total serum thyroxine concentration, urinalysis, 
aerobic urine culture, and non-invasive systolic blood pressure.  In addition, feline pancreatic 
lipase immunoreactivity (fPLI), tripsin-like immunoactivity (TLI), cobalamin, and folate were 
measured.  In three of the cats, a brief ultrasound of the cranial abdomen, specifically evaluating 
the pancreas, duodenum, and biliary tree was performed.   
5.2.3 Study Design 
Patients were randomly assigned to one of two groups in a double-blinded, placebo-
controlled study design.  Group A cats were treated with porcine zinc insulin (Vetsulin®, 
Intervet) twice daily (q12hr) at an initial dose of 0.25IU/kg and exenatide (Byetta®, Amylin 
Pharmaceuticals) twice daily (q12hr) at a dose of 2mcg/kg.  Group B cats were treated with the 
same insulin formulation and dose but were administered sterile saline in an equivalent volume to 
that of group A exenatide treatment.  Diet was not controlled and owners were free to continue 
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feeding the patient’s current diet, however, a therapeutic diet designed for the diabetic cat was 
available if owner’s elected to modify the patient’s diet.a   
Patients were examined every two weeks over a 12-week study period.  At each visit, a 
complete physical exam and in-hospital serum blood glucose curve were performed starting at the 
time of morning insulin dose and continuing for 4-6 hours after the nadir blood glucose was 
identified (8-12 hour total duration per curve).  Blood glucose was measured with the 
AlphaTRAK® (Abbott Animal Health, Illinois, USA) glucometer using capillary blood obtained 
by ear pinna prick.  Serum fructosamine was evaluated at least once monthly, but could be 
requested at any recheck visit to assist in making adjustments in insulin dose.  Owners were asked 
to log any changes in the pet’s behavior daily and immediately report any gastrointestinal signs of 
vomiting, diarrhea, or anorexia.   
Insulin was initially dosed at 0.25IU/kg rounded to the nearest 0.5IU using 0.3cc U-40 
syringes to facilitate accurate dosing of the small volumes of drug prescribed.  After each visit the 
insulin dose was adjusted based on clinical signs, blood glucose curve, and serum fructosamine. 
(Figure 5.1)  Adequate glycemic control was defined as a reduction in clinical signs of polyuria 
and polyphagia along with serum fructosamine less than 550µMol and a glucose curve nadir 
between 100 and 200mg/dl.  Insulin doses were increased by 25% or 0.5IU in cases of inadequate 
control and decreased by 25% with evidence of over-control (nadir glucose <100mg/dl, clinical 
signs of hypoglycemia at home). 
At the end of the study period, fructosamine, PLI, and a blood glucose curve were 
measured.  Study drug was discontinued after the final visit at week 12 but insulin treatment 
continued with porcine zinc insulin on a twice-daily schedule.  
5.2.4 Statistical Analysis 
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Data are presented as mean and standard deviation (mean ± SD).  Data was evaluated 
using a software program (SigmaPlot, Systat Software Inc, San Jose, CA, USA).  Results for 
weight, fructosamine, fPLI, and insulin dose were evaluated using a two-way repeated measures 
ANOVA with Tukey Pairwise Multiple Comparison post-hoc analysis.  Differences were 
considered significant when the calculated p-value was <0.05.  A post-hoc power and sample size 
analysis was performed for the outcome variables of ending fructosamine and insulin dose.  For 
this analysis, the values of alpha and beta were assumed to be 0.05 and 0.20 respectively.   
5.3 Results 
Thirteen eligible cats were presented during the study period. A diagnosis of diabetes 
mellitus was confirmed in all 13 patients.  In one case, a diagnosis of hypertension was made on 
initial examination (systolic blood pressure 190mmHg) prior to any additional diagnostics being 
completed.  The owner did not return for a follow-up examination to verify the diagnosis and so 
the patient was not enrolled. Twelve cats were enrolled in the study including 6 castrated males 
and 6 spayed females aged 10.7 ± 2.2 years. (Figure 5.2) 
Two cats failed to complete the entire study protocol.  One cat was withdrawn by his 
owner due to marked anorexia that was attributed to study drug.  A five day drug holiday was 
recommended during which time the patient’s appetite and attitude returned to normal.  The drug 
was re-started for two days during which time the patient again became profoundly anorexic and 
his owner elected to remove him from the study.  A second cat failed to show adequate response 
to insulin, despite a continuously escalating insulin dose.  Although she had no clinical signs 
associated with acromegaly, an elevated IGF-1 of 257nmol/L (reference range = 12-92nmol/L) 
was consistent with a diagnosis of acromegaly.  A diagnosis of a concurrent endocrinopathy 
necessitated removal of that patient from the study.   
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A summary of clinical pathologic findings is presented in Figure 5.3.  Random treatment 
group assignments resulted in equal numbers of spayed females and neutered males in each 
treatment group.  There was no difference between the exenatide or saline groups regarding 
starting or ending body weights. (p=0.84, 0.99 respectively).  Although five of six cats in the 
exenatide group lost weight (mean weight change -0.19 ± 0.32kg) compared to only 2/4 control 
cats (mean weight change 0.025 ± 0.173kg), the difference was not significant (saline group 
p=0.86, exenatide group p=0.13).   
Serum fructosamine concentration was not different between exenatide (635.7 ± 114.1) 
and saline treated controls (569.6 ± 111.6) at the start of the study period (p=0.81).  Fructosamine 
was also not significantly different between the two groups after 12 weeks. (exenatide: 557.2 ± 
120.06, saline: 499.8 ± 97.52, p=0.39)  Mean fructosamine concentrations decreased within each 
group over 12 weeks, however, the differences between starting and ending means within groups 
were not significant (exenatide group p=0.12, saline group p=0.07)   
Pancreatic lipase activity was similar between both exenatide treated and saline treated 
cats at the beginning and end of the study. (p=0.53, 0.38 respectively)  Mean serum PLI did 
decrease slightly in both groups during treatment.  In the exenatide group, PLI decreased from 
10.10 ± 9.21 to 9.20 ± 10.43, but this change was not significant. (p=0.51)  In the saline treated 
group, PLI decreased from 7.62 ± 4.14 to 3.05 ± 1.64, but this change was also not significant. 
(p=0.46)   
Initial insulin dose was assigned based on body weight.  Mean insulin dose (IU/kg) 
increased in both groups (0.54 ± 0.20 in control and 0.44 ± 0.27 in exenatide treated cats) and the 
difference in dose between groups was not significant at 12 weeks. (p=0.4)  
The results of the post-hoc sample size analysis suggests that 45 cats in each group would 
be required to detect a difference in serum fructosamine and at least 70 cats in each group would 
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be needed to detect a difference in insulin dose requirements.  Limited resources and difficulty 
recruiting naïve diabetic cats for the study made enrolling additional patients unfeasible. 
5.4 Discussion 
The aim of this study was to evaluate the utility of the addition of an incretin mimetic to 
standard insulin therapy.   We hypothesized that the addition of a GLP-1 mimetic to standard 
insulin therapy would improve diabetic control resulting in lower average serum glucose and 
consequently lower fructosamine concentration, weight loss, and reduce the requirement for 
exogenous insulin.  
One of the 12 cats enrolled in the study experienced an adverse event attributed to the 
drug.  In that case, the patient was withdrawn by the owner after a report of severe anorexia that 
resolved upon removal of the drug and returned when drug was re-introduced at full dose.  In 
people, it is recommended that a smaller dose be used during the first month and then increased 
for the duration of therapy to decrease the incidence of gastrointestinal side-effects.20 Based on 
this recommendation, it is possible the drug could have been re-introduced at a reduced dose for 
several weeks and then increased the dose if no anorexia was seen.          
Exenatide, like GLP-1, has an activating effect on the satiety center of the brain.  In 
clinical trials, exenatide (Byetta®) was associated with between 1 and 3% incidence of decreased 
appetite in people.  Gastrointestinal side effects including vomiting, diarrhea, and nausea occur in 
as many as 41% of people taking the drug.21 In a recent meta-analysis, exenatide was found to 
correlate to a weight loss of 1.37kg (95% CI: -2.22kg, -0.52kg) in people.22 Feline diabetes 
mellitus is frequently diagnosed in obese cats and weight reduction is associated with increased 
insulin sensitivity.  Therefore, weight loss may be a positive result of increased satiety signals.  
Not all diabetic cats, however, are overweight, and in the case of an excessively thin cat, weight 
loss would be detrimental.  Weight loss occurred in five of 6 cats treated with exenatide.  One cat 
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from the exenatide group gained 10% of his body mass during the 12 weeks, however this cat 
began the study at a very low body condition and was still thin upon completion of the study.  
Weight loss in the remaining five exenatide treated cats ranged from 2.6-10.9% of initial body 
weight.   
 Our initial insulin dose was conservative and dose increases were expected within the 
first weeks of therapy.  At the end of the 12-week study, mean insulin dose between the two 
groups was not different.  If exenatide had improved glycemic control as hypothesized, we would 
have expected an insulin-sparing effect of the drug and a lower mean dose of insulin required to 
maintain euglycemia.  This finding suggests that exenatide did not allow for a lower insulin dose 
and, therefore, did not result in improved glycemic control. 
A black-box warning from the United States Food and Drug Administration was issued 
for Byetta® in 2008 after 36 cases of necrotizing hemorrhagic pancreatitis were associated with 
exenatide use in people between 2007 and 2008.  Multiple meta-analyses performed since that 
warning was issued have failed to identify an association with exenatide use and increased risk of 
pancreatitis in people.  However, because of the historical concern, serum feline pancreatic lipase 
immunoactivity was used as a marker for pancreatitis in our patients.  Using a laboratory-defined 
cut-off of 3.5µg/L for normal PLI concentration, only two of 10 cats had normal PLI at all time-
points.  Serum PLI decreased over the 12 weeks in nearly all cats, regardless of treatment group, 
and there was no significant difference seen in PLI concentrations in cats treated with exenatide 
as compared to saline control.  This data is consistent with published literature suggesting 
pancreatitis is a common feature in diabetic cats.  It is important to note that PLI has a sensitivity 
of only 54% and a specificity of 67% in the diagnosis of chronic feline pancreatitis.23,24 It is 
unknown if the elevated PLI values seen in cats in this study are truly associated with clinically 
relevant pancreatitis.  Patients were observed closely by owners for signs of pancreatitis 
(anorexia, abdominal discomfort, vomiting) and any potential signs were reported.  In the single 
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patient with a report of anorexia, repeat fPLI values declined, suggesting that pancreatitis was less 
likely the cause of the episode.      
We did not control for diet in this study and variations in diet are likely to confound our 
data.  The importance of carbohydrate-restricted diets in the treatment of diabetic cats has been 
demonstrated in several studies.25-27 Carbohydrate restriction is associated with a more modest 
postprandial spike in blood glucose and lessens the demands on already taxed beta cells.  Diets 
low in carbohydrates and high in protein are associated with weight loss while still maintaining 
lean body mass, both of which are associated with improved insulin sensitivity.  Owners of 
patients in our study were counseled as to the importance of diet and suggestions for appropriate 
diabetic diets were made.  Where owners elected, a therapeutic diet designed for diabetic cats was 
available.  It is impossible to determine what role, if any, diet played in this study because of the 
small number of cats and the lack of accurate diet history. 
As discussed, feline diabetes is an insidious disease characterized by a very gradual 
decline in beta cell function and ability to produce insulin in amounts sufficient to maintain 
normoglycemia. It is therefore likely that most cats have some degree of beta cell function at the 
time of diagnosis.  Because of this, we sought a population of diabetic cats (newly diagnosed) 
most likely to still have functional beta cell mass remaining.  The unpredictable and variable 
nature of beta cell loss over time combined with cat behavior, owner attentiveness, and other 
comorbidities means that even the classification of “newly diagnosed diabetic cats” still 
represents mixed population of disease.  Much larger sample sizes may allow the ability to 
stratify patients more effectively and to identify specific subsets of patients more or less likely to 
respond to treatment.    
Finally, a major challenge for treating a diabetic cat is defining a “well controlled 
diabetic.”  Serum fructosamine, blood glucose curves, clinical signs reported by the owner, and 
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changes in body condition do not always correlate well with each other in the clinical setting.  
The clinical significance of a change in serum fructosamine is small compared to the subjective 
report of reduced PU/PD or improved interaction with family.  Therefore, just because a serum 
fructosamine value is “less than ideal” does not mean the patient may not be adequately 
controlled if all other data suggests adequate control.  In this study, we selected serum 
fructosamine and insulin dose at 12 weeks as our primary, objective outcome variables most 
likely to correspond to adequate disease control.  A more nuanced definition of diabetic control 
would require a much larger data set with multivariate analysis along with subjective evaluation 
of individual patients to determine if there may be clinical benefits to the use of GLP-1 mimetics 
that go beyond a single serum chemistry value. 
5.5 Conclusion 
The addition of exenatide to traditional insulin therapy was not associated with any 
significant changes in body weight, serum fructosamine, serum PLI, or exogenous insulin dose. 
However, our ability to detect differences was severely limited by the small sample size.   Our 
post hoc power analysis suggests that a much larger group of cast would be required to detect the 
fairly small changes in fructosamine and insulin dose detected in this study.  Because of these 
modest changes in outcome variables observed, additional value may be obtained by including 
subjective outcomes such as owner perceptions of diabetic control. 
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Figure 5.1. Decision making algorhythm for adjusting dose at each evaluation.   
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Weight (kg) BCS  
Treatment 
Group 
1 9 SF 5.04 7 Ex 
2 13 MN 4.58 4 Ex 
3 13 SF 3.93 4 Ex 
4 9 SF 4.28 4 Ex 
5 10 MN 6.5 8 Ex 
6 6 MN 4.26 3 Ex 
7 14 MN 3.9 3 Ex 
8 10 MN 3.05 3 Sal 
9 11 SF 7.0 9 Sal 
10 10 MN 4.7 3 Sal 
11 11 SF 3.5 3 Sal 
12 12 SF 6.41 8 Sal 
 
Figure 5.2.  Summary of signalment, body weight, and body condition score along with treatment 
group assignment. Patients seven and twelve did not complete the 12-week study period.  Body 
condition scores are assigned based on a nine-point scale, with 9/9 being morbidly obese.  





































































Figure 5.3. Data summary for all cats.  12 cats were enrolled, but only 10 cats completed all 12 
weeks of the study.  No significant differences were found between groups.  See text for 
individual p-values.  All values are mean ± standard deviation. †n=5 used in analysis due to 
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Diabetes mellitus is one of the most common endocrinopathies seen in cats.  It is the 
result of insufficient insulin activity within insulin-sensitive tissues to maintain euglycemia and is 
the result of both changes in peripheral insulin sensitivity and lack of adequate functional beta 
cell mass.  The loss of beta cell function occurs gradually over a period of months and years, and 
mechanisms of loss are incompletely understood in the cat.   
The purpose of the work described herein was three fold:  to identify some of the 
mechanisms associated with beta cell dysfunction in feline diabetes mellitus, to develop 
techniques for the use of freshly isolated feline islets for the study islet cell pathogenesis in cats, 
and to study the mechanisms and utility of GLP-1 mimetics as a therapy of feline diabetes 
mellitus.  Many aspects of the disease phenotype seen in cats are analogous to Type 2 diabetes 
mellitus in humans.  Because of these similarities, much of our understanding of the mechanisms 
of disease pathogenesis and treatment of feline diabetes is extrapolated from work done in 
humans and in rodent models of human disease.  Diabetes mellitus in both cats and people is a 
complex metabolic disease with no single cause or trigger.  In both species the disease is 
associated peripheral insulin resistance, increased adiposity, inappropriate diet, and loss of beta 
cell mass.  One of the most significant similarities is that cats are the only animals outside of 
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humans and non-human primates known to spontaneously produce pancreatic amyloid, making 
them particularly valuable as an animal model for human disease.   
The most significant mechanisms associated with beta cell failure in people can be 
generally grouped into 5 categories: gluco-lipotoxicity, inflammation, oxidative stress, amyloid 
accumulation, and endoplasmic reticulum (ER) stress.  To date, our assumptions regarding 
mechanisms of beta cell dysfunction in cats have largely been based on therapeutic outcomes, a 
hand-full of in vivo studies, and post-mortem examination.  For example, the phenomenon of 
“diabetic remission” in cats is well described and occurs in cats most frequently after establishing 
aggressive glycemic control early after disease diagnosis.  Moreover, in a single in vivo study, 
profound beta cell loss was described after a 10-day hyperglycemic clamp.  These findings 
provide strong evidence that glucotoxicity is an important mediator of beta cell dysfunction.   
Studies describing the presence of inflammation, oxidative stress, or ER stress in cats are lacking.  
The association of amyloid accumulations with diabetes in cats as well as people is well 
described.  There have not, however, been published studies testing the oligomeric amyloid 
hypothesis in cats. 
Because of the gaps in our knowledge of whether oxidative stress and inflammation play 
a role in the development of feline diabetes, we first set out to characterize the markers of 
inflammation, oxidative stress, and amyloid in the pancreatic islets of normal and diabetic cats.  
In this study, we were the first to characterize the presence of inflammatory cytokine signaling 
(namely, IL-1β), and oxidative modifications (4-hydroxynonenal) within the islets of non-
diabetic, apparently “healthy” cats.  In contrast, the islets of diabetic cats were essentially absent 
or effaced with amyloid, making it difficult to draw conclusions about the presence (or absence) 
of inflammation of oxidative modification.   
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Identifying widespread staining for IL-1β and oxidative modification in the form of 4-
HNE in healthy cats was unexpected.  Because the islets in the diabetics were completely effaced 
and conclusions about islet inflammation or oxidative medication could not be made, we 
investigated the possibility that inflammation and oxidative modification are processes occurring 
earlier in disease development and will be absent by the time the islet is completely destroyed.  
Samples of pancreas from cats enrolled in another, unrelated, study were available from before 
and after 12 weeks of induced obesity and hyperglycemia (conditions typical of cats early in 
development of diabetes).  The results from these paired samples suggest that obesity and 
hyperglycemia are associated with significant increases in inflammatory cytokine signaling and 
oxidative modification.  Thioflavin-stained sections from these same cats failed to detect any islet 
amyloid deposits.  These findings provides important clues to potential mechanisms of beta cell 
dysfunction not previously described in cats, namely the possible role of islet inflammation and 
oxidative stress and suggest that islet inflammation and oxidative stress may precede the 
development of amyloid.  However, as these cats were experimentally induced diabetics, the 
disease process seen may not mirror naturally occurring disease.   
Our next aim was to develop techniques for the isolation and culture of fresh feline 
pancreatic islets.  Our ability to study the causes of beta cell dysfunction in cats is limited by the 
lack of physiologically appropriate, species-specific assays.  Islet cell culture is commonly 
utilized in experiments studying the disease in humans and in rodent models of human disease.  
There is an array of various immortalized insulin producing cell lines available from rodent origin 
that can be very useful and primary islet culture is routinely utilized in pigs, people, and rodents.  
However, no such cell lines or islet isolation techniques exist for cats.   
The result of this work was a technique for the isolation of highly pure pancreatic islets in 
sufficient numbers to be useful for a variety of laboratory assays. The islets that were isolated 
maintained adequate viability over a period of at least 5 days.  Unfortunately, however, we were 
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unable to demonstrate reliable responsiveness to glucose stimulation.  This was despite extensive 
modification of the culture system and use of several different culture media, culture substrates, 
and combinations of growth factors and antioxidants.  The lack of reliable physiologic 
responsiveness does not, however, preclude the potential utility of freshly isolated pancreatic 
islets for assays evaluating other aspects of islet and beta cell physiology. 
The origin of the inconsistent response of isolated feline islets is unclear.  The 
“consistently inconsistent” nature of the islet function over many experiments over an extended 
period of time suggests that the reason for this failure lies in a treatment that all islets are exposed 
to: harvesting and transport conditions, isolation conditions, or culture conditions.  As discussed 
in chapter 3, one possible reason stems from the methods of organ harvesting and transport.  All 
cats were random-sourced and euthanized using the same protocol.  Although there is no reason 
to expect interference with either the drugs used for sedation (ketamine, xylazine) or euthanasia 
(phenytoin-free pentobarbital overdose), it is possible that one of these drugs may significantly 
alter the metabolism of the islets and inhibit function.  Cats euthanized using an alternative 
protocol would be required to test this hypothesis, but this was not possible given the restrictions 
on euthanasia protocols by the shelter staff.  Cold ischemic time was limited to as short a period 
as possible, but the extended travel to get the tissues back to the laboratory meant at least one and 
a half hours cold ischemia time.  It is possible that having the animals closer to the laboratory 
facility and potentially eliminating cold ischemia time may result in improved function.   
Hand picking islets represented the single longest portion of the isolation procedure, 
during which time the islets were at ambient temperature exposed to room air with dithizone in 
the culture media.  As an alternative to hand picking, density centrifugation must be re-visited.  
The small number of islets and apparently similar density of the islets to the exocrine tissue made 
our initial attempts at density centrifugation unsuccessful.  But experimentation with different 
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compounds, speeds, and specific gravities may enhance the speed of recovery and limit the 
exposure of freshly isolated islets to harsh conditions.   
A wide variety of culture media were tried during the optimization period prior to the 
experiments in chapter 3.  The two culture media commonly utilized for islets in the literature are 
RPMI, which is commonly recommend for rodent islets, and CMRL, which is commonly 
recommended for human islets.  The principle difference between these two media is the glucose 
concentration.  The glucose concentration of the RPMI media is 10mmol/l and CMRL is 
5.4mmol/l.  As no difference was appreciated initially, CMRL was selected as the culture media 
because the lower glucose concentration left room to more easily manipulate experimental 
glucose concentrations and it was assumed that feline islets would behave more similarly to 
human islets than to rodent islets in response to glucose.  Although fetal calf serum contains a 
number of growth factors, it is possible that feline islets require a specific combination that was 
not achieved in our experiments.  Of specific interest are IGF-1 and 2, HGF, melanocortins, and 
glucagon.  Glucagon has been shown to be a potent mediator of glucose stimulated insulin release 
in freshly isolated human islets.  The concentration of glucagon in media was not determined in 
our experiments. 
Collagenase tissue digestion can be very harsh to tissues and it is reasonable to expect 
collagenase digestion of the pancreas will alter islet morphology to some degree.  As was 
discussed in chapter 3, altered islet composition morphology was associated with altered 
physiologic response to glucose in human islets.  Morphology and cellular composition of our 
isolated islets was not assessed.  Positive staining for dithizone was consistent with zinc-laden 
beta cells of islets, but integrity of islet basement membrane or altered islet composition 
secondary to digestion was not evaluated.  Embedding of fresh islets for immunohistochemistry 
or electron microscopy is important to determining the composition of our isolated islets and any 
disruption in the islet connective tissue capsule.  The techniques needed to effectively embed and 
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section small populations of islets were not mastered during our experiments, and collaboration 
with histologists with experience in this technique would be invaluable to resolving our technical 
problems.   
Endoplasmic reticulum stress is a well-described mechanism believed to be associated 
with beta cell death in people and in rodent models.  Studies using human and rodent islets and 
rodent cell cultures have demonstrated that GLP-1 mimetics are associated with improvement of 
beta cell function in the face of ER stress.  Neither the role of ER stress nor the in vitro effects of 
GLP-1 mimetics have been evaluated in cats.  Therefore, we designed experiments to first 
determine the effects of the ER stress inducing drugs thapsigargin and tunicamycin on freshly 
isolated pancreatic islets.  Both drugs produced a predictable rise in caspase 3 activity, suggesting 
that ER stress can be chemically induced in our freshly isolated islets.  We were then able to 
document an attenuation of caspase 3 activity in islets co-cultured with exenatide in addition to 
the ER stress-inducing drug.  These results suggest that exenatide may have an islet cell sparing 
effect in freshly isolated feline islets exposed to ER stress.  Although the data was suggestive of a 
protective effect of exenatide in islets treated with thapsigargin and tunicamycin, the small 
number of experiments makes it difficult to draw strong conclusions from the available data.  
Additional experiments under similar culture conditions are necessary to provide the power 
necessary to draw conclusions about whether exenatide protects pancreatic islets from both 
thapsigargin and tunicamycin.  For reasons that may be related to our experiences in chapter 3 
(isolation of islets), not all groups of islets isolated for this experiment showed an expected 
activation of caspase-3 in response to the ER stress-inducing drug.  In fact, some control islets 
had relatively high base-line caspase-3 activation, suggesting activation of apoptotic pathways 
independent of the drugs.  Additional work optimizing isolation of islets may also help solve this 
complication as well.   
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Our final aim was to evaluate the effectiveness of adjunctive therapy with exenatide in 
addition to basal insulin in newly diagnosed feline diabetics.  Previous work completed by our 
group as well as by others suggested that exenatide was safe and as associated with a dose-
dependent effect of augmenting serum insulin in response to glucose challenge.  GLP-1 mimetics 
are routinely used in human Type 2 diabetics and have a proven record of safety and efficacy in 
improving quality of glycemic control in people.  For this aim we recruited newly diagnosed, 
uncomplicated feline diabetics presented to the teaching hospital.  A double-blind, placebo-
controlled study design was used and cats were either treated with insulin alone or insulin with 
the addition of exenatide given twice daily.  Recruitment proved to be a severely limiting factor, 
and the study was underpowered as a result.  On the whole, there was no effect of exenatide 
detected in treated cats when exenatide was added to basal insulin.  These results must be 
interpreted with caution, however, because of the small sample size.   
At the time of diagnosis, most cats will have some volume of beta cell mass that can 
potentially be restored to function, a concept supported by the potential for remission of clinical 
disease in cats.  Newly diagnosed cats, therefore, represent a heterogeneous population of cats 
with varying degrees of beta cell function superimposed on an already complicated genetic and 
metabolic backgrounds.  In order to account for this wide ranging population, much larger studies 
will be required to provide adequate power to help identify which patients are more likely to 
benefit from incretin mimetic therapy.  There are currently no tools available to quantify the 
actual beta cell reserve of a patient.  Cats with little or no beta cell is unlikely to benefit 
significantly from exenatide therapy in terms of providing improved glycemic control as either a 
mono or adjunct therapy in a diabetic cat. However, in cats diagnosed early, cats in remission, or 
in “pre-diabetic” cats with impaired beta cell function, it is reasonable to expect a fairly large beta 
cell population remains and exenatide therapy may provide valuable support and improved 
outcomes by avoiding clinical signs of feline diabetes.  Despite our limitations due to under-
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powered data, it is reasonable to consider that that any difference in treatment outcomes in cats 
using this study design is likely to be small and clinically insignificant.  Future studies with 
exenatide should take into consideration the importance of controlling for diet (a very important 
factor in the degree of post-prandial hyperglycemia), the value of longer-acting insulin (e.g. 
glargine), and the benefit of aggressive glycemic control immediately after diagnosis.  Addressing 
each of these concerns is expected to improve treatment outcomes overall.  Additionally, it may 
be unreasonable to expect a benefit of incretin therapy to be apparent after only 12 weeks of 
therapy without addressing the factors listed above.  Perhaps overall improved glycemic control 
will be synergistic with incretin therapies and more significant long-term benefits can be achieved 
The epidemic of feline diabetes is only expected to continue growing.  Improved diets, 
more active lifestyles, and improved insulin formulations have improved our ability to provide 
long-term support and extended quality of life for diabetic cats.  Our understanding of the root 
causes of the disease in cats is still developing.  The availability of a technique for producing 
highly pure isolated feline islets provides a valuable tool for the study of beta cell dysfunction and 
the potential benefits of incretin therapy on beta cell function.  The results of the work described 
here suggest that inflammation, oxidative stress, and misfolding IAPP all play a role in the 
development of beta cell dysfunction in the cat and that GLP-1 mimetic therapy may protect 
feline islets from ER stress which is known to play a role in beta cell loss in people.  Our 
understanding of the best clinical application of GLP-1 mimetics such as exenatide is still 
developing and more robustly powered clinical trials are necessary to determine which subsets of 
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